 
 
A Multicenter, Adaptive, Randomized Blinded Controlled Trial o f the Safety and 
Efficacy of Investigational Therapeutics for the Treatment of COVID -19  
in Hospitalized Adults  
  
Short Title: Adaptive COVID- 19 Treatment Trial (ACTT)  
   
DMID Protocol Number:  20-0006 
 
Sponsor :  
Division of Microbiology and Infectious Diseases (DMID), 
National Institute of Allergy and Infectious Diseases,  
National Institutes of Health  
 
Version Number: 3.0 
 
2 April  2020 
 
   
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 2 of 65 STATEMENT  OF COMPLIANCE  
Each institution engaged in this research will hold a current Federalwide Assurance (FWA) 
issued by the Office of Human Research Protection (OHRP) for federally funded research. The 
Institutional Review Board ( IRB)/Independent or Institutional Ethics Committee (IEC) must be 
registered with OHRP as applicable to the research.   
 
The study will be carried out in accordance with the following as applicable: 
• All National and Local Regulations and Guidance applicable at each site 
• The International Council for Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) E6(R2) Good Clinical Practice, and the 
Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research  
• United States  (US) Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of 
Human Subjects 
• US Food and Drug Administration (FDA) Regulations: 21 CFR Part 50 (Protection of 
Human Subjects), 21 CFR Part 54 (Financial Disclosure by Clinical Investigators), 21 CFR Part 56 ( IRBs ), 21 CFR Part 11, and 21 CFR Part 312 (Investigational New Drug 
Application), and/or 21 CFR 812 (Investigational Device Exemptions) 
• The polici es and procedures of National Institutes of Health (NIH) Office of Extramural 
Research and Division of Microbiology and Infectious Diseases (DMID) 
 The signature below provides the necessary assurance that this study will be conducted according to all stip ulations of the protocol including statements regarding confidentiality, and 
according to local legal and regulatory requirements, US federal regulations , and ICH E6(R2) 
GCP guidelines.  
Site Investigator  Signature : 
 
 
Signed:   Date:   
 Name  and Title    
  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 3 of 65 TABLE  OF CONTENTS  
 
STATEMENT OF COMPLIANCE  ................................................................................................ 2 
TABLE OF CONTENTS  ................................................................................................................ 3 
LIST OF TABLES  .......................................................................................................................... 5 
LIST OF FIGURES  ........................................................................................................................ 6 
1. PROTOCOL SUMMARY ...................................................................................................... 7 
1.1 Synopsis .......................................................................................................................... 7 
1.2 Schedule of Assessments  .............................................................................................. 13 
1.3 Study Schema................................................................................................................ 14 
2. INTRODUCTION  ................................................................................................................ 14 
2.1 Study Rationale ............................................................................................................. 14 
2.2 Background ................................................................................................................... 14 
2.2.1 Purpose of Study ................................................................................................... 14 
2.2.2 Potential Therapeutics  ........................................................................................... 15 
2.3 Risk/Benefit Assessment  .............................................................................................. 15 
2.3.1 Known Potential Risks .......................................................................................... 15 
2.3.2 Potential Risks of Remdesivir  ............................................................................... 16 
2.3.3 Known Potential Benefits ..................................................................................... 17 
2.3.4 Assessment of Potential Risks and Benefits  ......................................................... 17 
3. OBJECTIVES AND ENDPOINTS  ...................................................................................... 17 
4. STUDY DESIGN .................................................................................................................. 20 
4.1 Overall Design  .............................................................................................................. 20 
4.2 Scientific  Rationale for Study Design........................................................................... 21 
4.3 Justification for Dose .................................................................................................... 22 
5. STUDY POPULATION  ....................................................................................................... 22 
5.1 In
clusion Criteria  .......................................................................................................... 22 
5.2 Exclusion Criteria  ......................................................................................................... 23 
5.2.1 Exclusion of Specific Populations ........................................................................ 23 
5.3 Inclusion of Vulnerable Subjects .................................................................................. 24 
5.4 Lifestyle Considerations ............................................................................................... 24 
5.5 Screen Failures  .............................................................................................................. 24 
5.6 Strategies  for Recruitment and Retention ..................................................................... 25 
5.6.1 Recruitment  ........................................................................................................... 25 
5.6.2 Retention  ............................................................................................................... 25 
5.6.3 Compensation Plan for Subjects ........................................................................... 25 
5.6.4 Costs ...................................................................................................................... 25 
6. STUDY PRODUCT .............................................................................................................. 25 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 4 of 65 6.1 Study Product(s) and Administration – GS -5734 (Remdesivir) and placebo ............... 25 
6.1.1 Study Product Description .................................................................................... 25 
6.1.2 Dosing and Administration ................................................................................... 26 
6.1.3 Dose Escalation  ..................................................................................................... 26 
6.1.4 Dose Modifications ............................................................................................... 26 
6.1.5 Overdosage ........................................................................................................... 26 
6.2 Preparation/Handling/Storage/Accountability .............................................................. 27 
6.2.1 Acquisition and Accountability ............................................................................ 27 
6.2.2 Formulation, Appearance, Packaging, and Labeling ............................................ 27 
6.2.3 Product Storage and Stability................................................................................ 28 
6.2.4 Preparation  ............................................................................................................ 28 
6.3 Measures to Minimize Bias: Randomization and Blinding  .......................................... 29 
6.4 Study Intervention Compliance .................................................................................... 29 
6.5 Concomitant Therapy.................................................................................................... 29 
6.5.1 Rescue Medicine  ................................................................................................... 30 
6.5.2 Non-Research Standard of Care ............................................................................ 30 
7. STUDY INTERVENTION DISCONTINUATION AND SUBJECT 
DISCONTINUATION/WITHDRAWAL ..................................................................................... 30 
7.1 Halting Criteria and Discontinuation of Study Intervention ......................................... 30 
7.1.1 Individual Infusion Halting ................................................................................... 30 
7.1.2 Study Halting ........................................................................................................ 31 
7.2 Withdrawal from the Study ........................................................................................... 31 
7.3 Lost to Follow- Up ......................................................................................................... 31 
8. STUDY ASSESSMENTS AND PROCEDURES  ................................................................ 31 
8.1 Screening and Efficacy Assessments  ............................................................................ 31 
8.1.1 Screening Procedures ............................................................................................ 31 
8.1.2 Efficacy Assessments ............................................................................................ 33 
8.1.3 Expl
oratory assessments ....................................................................................... 35 
8.2 Safety and Other Assessments  ...................................................................................... 36 
8.2.1 Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings .................................................................................................. 38 
8.2.2 Unscheduled Visits ............................................................................................... 38 
8.3 Adverse Events and Serious Adverse Events ............................................................... 38 
8.3.1 Definition of Adverse Event (AE) ........................................................................ 38 
8.3.2 Definition of Serious Adverse Event (SAE) ......................................................... 39 
8.3.3 Suspected Unexpected Serious Adverse Reactions (SUSAR) .............................. 39 
8.3.4 Classification of an Adverse Event ....................................................................... 39 
8.3.5 Time Period and Frequency for Event Assessment and Follow- Up ..................... 40 
8.3.6 Serious Adverse Event Reporting ......................................................................... 41 
8.3.7 Reporting of Pregnancy ........................................................................................ 42 
8.4 Unanticipated Problems ................................................................................................ 42 
8.4.1 Definition of Unanticipated Problems .................................................................. 42 
8.4.2 Unanticipated Problem Reporting......................................................................... 42 
9. STATISTICAL CONSIDERATIONS .................................................................................. 42 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 5 of 65 9.1 Statistical Hypotheses  ................................................................................................... 43 
9.2 Sample Size Determination ........................................................................................... 43 
9.3 Populations for Analyses .............................................................................................. 47 
9.4 Statistical Analyses  ....................................................................................................... 47 
9.4.1 General Approach  ................................................................................................. 47 
9.4.2 Analysis of the Primary Efficacy Endpoint .......................................................... 47 
9.4.3 Analysis of the Secondary Endpoint(s)................................................................. 47 
9.4.4 Safety Analyses  ..................................................................................................... 48 
9.4.5 Baseline Descriptive Statistics  .............................................................................. 48 
9.4.6 Planned Interim and Early Analyses ..................................................................... 48 
9.4.7 Sub-Group Analyses ............................................................................................. 49 
9.4.8 Exploratory Analyses ............................................................................................ 49 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ... 50 
10.1 Regulatory, Ethical, and Study Oversight Considerations............................................ 50 
10.1.1 Informed Consent Process .................................................................................... 50 
10.1.2 Study Termination and Closure ............................................................................ 52 
10.1.3 Confidentiality and Privacy .................................................................................. 52 
10.1.4 Secondary Use of Stored Specimens and Data ..................................................... 53 
10.1.5 Key Roles and Study Governance ........................................................................ 53 
10.1.6 Safety Oversight.................................................................................................... 53 
10.1.7 Clinical Monitoring ............................................................................................... 54 
10.1.8 Data Handling and Record Keeping ..................................................................... 54 
10.1.9 Protocol Deviations ............................................................................................... 56 
10.1.10 Publication and Data Sharing Policy .................................................................... 56 
10.1.11 Human Data Sharing Plan ..................................................................................... 56 
10.1.12 Publication  ............................................................................................................ 57 
10.1.13 Conflict of Interest Policy  ..................................................................................... 57 
10.2 Addi
tional Considerations ............................................................................................ 57 
10.2.1 Research Related Injuries  ..................................................................................... 57 
10.3 Abbreviations ................................................................................................................ 57 
10.4 Protocol Amendment History ....................................................................................... 59 
11. REFERENCES  ................................................................................................................. 62 
 
LIST  OF TABLES  
Table 1. Schedule of Assessments (SOA)  .................................................................................... 13 
Table 2. National Early Warning Scor e (NEWS)  ......................................................................... 34 
Table 3. Venipuncture Volumes1 .................................................................................................. 38 
Table 4 Power under different rate ratios and probabilities of recovering by 28 days. ................ 43 
Table 5. Possible scenarios for the distribution of ordinal outcomes for the control arm at Day 15........................................................................................................................................................ 45 Table 6. Sample size calculations for scenarios in Table 5 for a two -arm study assuming 85% 
power, a two-sided type I error rate of 5%, and various true odds ratios. .................................... 45 Table 7. Treatment ordinal outcome proportions under an odds ratio of 1.75 for five scenarios in....................................................................................................................................................... 46 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 6 of 65  
 
LIST  OF FIGURES  
No table of figures entries found.   
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 7 of 65 1. PROTOCOL  SUMMARY 
1.1 Synopsis  
Rationale for Proposed Clinical Study  
In December 2019, the Wuhan Municipal Health Committee identified an outbreak of viral 
pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been designated severe acute respiratory syndrome coronavirus 2 ( SARS -CoV -2), and the disease caused by this virus has been designated 
Coronavirus Disease 2019  (COVID-19). There were 59 confirmed cases o n January 5, 2020, 278 
cases on January 20, 2020, rising to more than 318,000 confirmed cases and 13,000 deaths as of 
March 22 , 2020 according to various international health reporting agencies. Currently there are 
no approved therapeutic agents available for coronaviruses.  
 
Study Design  
This study is an adaptive, randomized, double-blind, placebo -controlled trial to evaluate the 
safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted in up to  approximately 100 sites  globally. 
The study will compa re different investigational therapeutic agents to a control arm . There will 
be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm 
for comparison(s) with new experimental treatment(s) . Any such change would be accompanied 
by an updated sample size.  Because background standards of supportive care may 
evolve/improve over time as more is learned about successful management o f COVID -19, 
comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent D ata and Safety Monitoring B oard (DSMB) will actively monitor interim data to 
make recommendations about early study closure or changes to study arms.   The initial sample size is projected to be 572 subjects to achieve 400 subjects with a “ recovered” 
status (per the primary objective) . The primary analysis will be based on those subjects enrolled 
in order to 400 recoveries.  An additional analysis of the moderate severity subgroup (those with baseline status of “Hospitalized, requiring supplemental oxygen” or “Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care”)  is also of public health importance. Hence, enrollment will be permitted until the date of April 20, 2020 to ensure 400 recoveries and provide additional data about this important subgroup. With recent enrollment rates, the total sample size m ay be 600 to over 800.  
 Subjects will be assessed daily while hospitalized. If the subjects are discharged from the 
hospital, they will have a  study visit at Days 15, 22, and  29 as an outpatient. For discharged 
subjects, i t is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory 
tests and OP swab and blood (serum only) samples for secondary research  as well as  clinical 
outcome data. However , infection control or other restrictions may limit the ability of the subject 
to return to the clinic.  In this case, Day 15 and 29 visits may be conducted by phone, and only 
clinical data will be obtained . The Day 22 visit does not have laboratory tests or collection of 
samples  and may  also be conducted by phone.  
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 8 of 65 All subjects will undergo a series of efficacy, safety, and laboratory assessments. Safety 
laboratory tests and blood (serum and plasma) research  samples and oropharyngeal (OP) swabs 
will be obtained on Days 1 (prior to infusion) and Days  3, 5, 8, and 11 (while hospitalized) . OP 
swabs and blood (serum only) plus safety laboratory tests will be collected on  Day 15 and 29 (if 
the subject attends an  in-person visit or are still hospitalized).  
 The primary outcome is time to recovery by Day 29 (see table below for definition based on the ordinal scale).  A key secondary outcome evaluates treatment- related improvements in the 8 -point 
ordinal scale at Day 15. As little is known about the clinical course of COVID -19, a pilot study 
will be used for a blinded sa mple size reassessment  (see section 9 for more details).   
 
Study Objectives  
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
To evaluate the clinical efficacy, as assessed 
by time to recovery, of different investigational therapeutics as compared to the control arm. Day of recovery is defined as the first day on 
which the subject satisfies one of the following three categories from the ordinal scale:  
• Hospitalized, not requiring supplemental 
oxygen - no longer requires ongoing medical care;  
• Not hospitalized, limitation on activities 
and/or requiring home oxygen; 
• Not hospitalized, no limitations on 
activities.  
Recovery is evaluated up until Day 29.  
Key Secondary   
To evaluate the clinical efficacy of different 
investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8 -
point ordinal scale) at Day 15 
 
  • Death;  
• Hospitalized, on invasive mechanical ventilation or ECMO; 
• Hospitalized, on non- invasive ventilation 
or high flow oxygen devices; 
• Hospitalized, requiring supplemental oxygen; 
• Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID -19 related or otherwise);  
• Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;  
• Not hospitalized, limitation on activities and/or requiring home oxygen; 
• Not hospitalized, no limitations on 
activities.  
Additional  Secondary    
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 9 of 65 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
1. To evaluate the clinical efficacy of 
different investigational therapeutics as 
compared to the control arm as assessed by: 
• Clinical Severity  
o Ordinal scale:  
 Time to an improvement of one category and two categories from Day 1 (baseline)  using an ordinal 
scale.  
 Subject clinical status using ordinal scale at Days 3, 5, 8, 11, 15, 22, and 29.  
 Mean change in the ordinal scale from Day  1 to Days 3, 5, 8, 11, 15, 
22, and 29. 
  
  
• Clinical outcome assessed using ordinal scale daily while hospitalized and on Day s 
15, 22, and 29. 
   
    
o National Early Warning Score 
(NEWS):  
 Time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.  
 Change from Day 1  to Days 3, 5, 8, 
11, 15, and 29 in NEWS.  
  
 
• NEWS assessed daily while hospitalized 
and on Days 15 and  29. 
o Oxygenation:  
 Oxygenation use up to Day 29. 
 Incidence and duration of new 
oxygen use during the study. 
  
• Days of supplemental oxygen (if applicable) up to Day 29 
 
o Non-invasive ventilation/high flow 
oxygen: 
 Non-invasive ventilation/high flow 
oxygen use up to Day 29. 
 Incidence and duration of new non-invasive ventilation or high flow oxygen use during the study. 
 • Days of non -invasive ventilation /high 
flow oxygen (if applicable)  up to Day 29 
o Invasive Mechanical Ventilation / 
extracorporeal membrane oxygenation (ECMO):  
 Ventilator / ECMO use up to Day 
29.  
• Days of invasive mechanical ventilation /ECMO  (if applicable)  up to 
Day 29. 
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 10 of 65 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
 Incidence and duration of new 
mechanical ventilation or ECMO use 
during the study.  
 
• Hospitalization  
o Duration of hospitalization (days).  
  
• Days of hospitalization up to Day 29 
• Mortality  
o 14-day mortality  
o 29-day mortality  
  
• Date and cause of death (if applicable)  
 
2. To evaluate the safety of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Cumulative incidence of SAEs through Day 29. 
• Cumulative incidence of Grade 3 and 4 clinical and/or laboratory AEs through Day 29. 
• Discontinuation or temporary suspension of infusions (for any reason) 
• Changes in white blood cell (WBC) 
count with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and  prothrombin time (PT) over 
time (analysis of lab values in addition 
to AEs noted above).   
  
• SAEs  
• Grade 3 and 4 AEs  
• WBC  with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT on Day 1; Days 3, 5, 8, and 11 (while hospitalized); 
and Days 15 and 29 (if attends in-person 
visit or still hospitalized) . 
 
Exploratory   
To evaluate the virologic efficacy of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Percent of subjects with SARS-CoV-2 detectable in OP sample at Days 3, 5, 8, 11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in OP 
sample at Days 3, 5, 8, 11, 15, and 29. 
• Development of resistance of SARS-CoV-2 in OP sample at Days 3, 5, 8, 11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in 
blood at Days 3, 5, 8, and 11. 
  
 
 
• Qualitative and quantitative polymerase 
chain reaction (PCR)  for SARS -CoV-2 in 
OP swa b on Day 1; Days 3, 5, 8, and 11 
(while hospitalized); and Days 15 and 29 
(if attends in -person visit or still 
hospitalized). 
• Qualitative and quantitative PCR for 
SARS -CoV-2 in blood on Day 1 ; Days 3, 
5, 8, and 11 (while hospitalized). 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 11 of 65  
 
Inclusion Criteria  
1. Admitted to a hospital with symptoms suggestive of COVID-19 infection. 
2. Subject (or legally authorized representative) p rovides informed consent prior to 
initiation of any study procedures. 
3. Subject (or legally authorized representative ) understands and agrees to comply with 
planned study procedures. 
4. Male or non-pregnant female adult ≥18 years of age at time of enrollment. 
5. Has laboratory -confirmed SARS -CoV-2 infection as determined by PCR or other 
commercial or public health assay in any specimen , as documented by either of the 
following:  
• PCR positive in sample collected < 72 hours prior to randomization; OR  
• PCR positive in sample collected ≥ 72 hours prior to randomization, documented 
inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited 
testing capacity, results taking > 24 hours, etc.). AND progressive disease suggestive of ongoing SARS -CoV-2 infection. 
6. Illness of any duration, and a t least one of the following: 
• Radiographic infiltrates by ima ging (chest x- ray, CT scan, etc.) , OR  
• SpO2 ≤ 94% on room air , OR  
• Requiring supplemental oxygen, OR 
• Requiring mechanical ventilation . 
7. Women of childbearing potential must agree to either abstinence or  use at least one 
primary form of contraception not including hormonal contraception from the time of screening through Day 29 .  
8. Agrees to not participate in another clinical trial for the treatment of COVID -19 or 
SARS -CoV-2 through Day 29. 
 
Exclusion C riteria  
1. ALT  or AST > 5 times the upper limit of normal. 
2. Estimated glomerular filtration rate (eGFR ) < 30 ml/min  (including patients receiving 
hemo dialysis  or hemofiltration ). 
3. Pregnancy or breast feeding. 
4. Anticipated discharge from the hospital or transfer to another hospital which is not a 
study site within 72 hours. 
5. Allergy to any study medication. 
 
Study Phase  
• Phase 3 
 
Study Population 
Hospitalized adults (≥18 years  old) with  COVID -19. 
 
Study Sites  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 12 of 65 There will be up to approximately  100 sites  globally. Site selection will be  determined as 
information becomes available about the epidemiology of COVID- 19. Multiple sites will be 
IRB-approved, but site activation will be dependent on the incidence of COVID-19 at the site.  
 
Study Intervention  
The study is designed to evaluate mul tiple interventions.  Investigational therapeutics  will be 
assessed for their incorporation into the trial based on in vitro and preclinical in  vivo data. 
 
Initially, the trial will have  two arms  and subjects will be randomized to receive either active 
product or placebo as follows :  
• Remdesivir will be administered as a 200 mg intravenous (IV) loading dose on Day 1, 
followed by a 100 mg once-daily IV maintenance dose for the duration of the 
hospitalization  up to a 10- day total course.  
• A placebo will be given at an equal volume at the same schedule.   
 The study will randomize subjects  1:1 to placebo or investigational product. If additional arms 
are added to or dropped from the trial, randomization will proceed with an equal probability of assignment to each of the remaining arms. As new interventions are added, the protocol will be amended and reviewed by IRB/IEC and applicable regulatory agencies before implementation. The current protocol, however, does lay out the general principles of how the m ulti-intervention 
trial would be implemented.   
 
Study Duration  
The study will last for up to 3 years.   
Participant Duration  
An individual subject will complete the study in about 29 days, from screening at Day -1 or 1 to follow-up on Day 29 ± 3 days.   
Safety  
• Given the potential severity of COVID-19 and limited information about the expected 
clinical course , there are no pre- specified  study stopping rules (except as noted under 
DSMB) . A subset of the protocol team will review blinded pools of Grade 3 and 4 AE / 
SAE data every 2 weeks. If there is a pattern of unexpected AEs  that is out of proportion 
to the current understanding of the natural history of the disease, the DSMB will be asked to review unblinded safety data in an ad hoc meeting. 
• The DSMB will have access to safety data electronically after every 50 subjects  and will 
have formal safety/efficacy reviews after approximately 200 subjects  have met recovered 
status .  Additionally, the DSMB will be  available for ad hoc  reviews for safety concerns  
as described above. The study will not stop enrollment awaiting these DSMB  reviews , 
though the DSMB may recommend temporary or permanent cessation of enrollment based on their safety reviews. 
    
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 13 of 65  
1.2 Schedule of Assessments  
Table 1. Schedule of Assessments (SOA)  
  Screen  Baseline  Study Intervention Period  Follow -up Visits  
Day +/ - Window  −1 or 1 1 Daily until hospital 
discharge  157  
± 2 227 
± 3 297 
± 3 
ELIGIBILITY        
Informed consent  X      
Demographics & Medical History  X      
Targeted physical exam  X      
Review SARS -CoV -2 results  X      
       
STUDY INTERVENTION        
Randomization   X     
Administration of remdesivir or 
control   Daily until discharge or 10 days . No 
study product given after Day 10.     
      
STUDY PROCEDURES        
Vital signs including SpO 2  X4 Daily until discharge  X7  X7 
Clinical data collection1   X4 Daily until discharge  X7 X7 X7 
Adverse event evaluation   X4 Daily until discharge  X7 X7 X7 
Concomitant medication review   X4 From Day -7 to Day 11     
       
SAFETY LABORATORY        
Safety hematology, chemistry and 
liver tests X2,3 X4,5,6 Day 3, 5, 8, 11 (all ± 1 
day) if hospitalized5,6 X7  X7 
Pregnancy test for females of 
childbearing potential  X2,3      
       
RESEARCH LABORATORY        
Blood for plasma to test for PCR 
SARS -CoV -2  X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospitalized     
Oropharyngeal swab 8  X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospitalized  X7  X7 
Blood for serum (secondary 
research)   X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospitalized  X7  X7 
Notes:  
1 Refer to Section 8.1 of the protocol for details of clinical data to be collected including ordinal score, NEWS, oxygen requirement, mechanical ve ntilator 
requirement, etc. 
2 Screening laboratory tests include: AL T, AST, creatinine (and calculate an estimated glomerular filtration rate (eGFR) the formula used is determined by 
the sites, but should be consistent throughout the study), and pregnancy test.  
3 Laboratory tests performed in the 48 hours prior to enrollm ent will be accepted for determination of eligibility.  
4 Baseline assessments should be performed prior to  first infusion . Laboratory tests performed as part of routine clinical care in the 24 hours prior to first 
dose will be accepted for the baseline saf ety laboratory tests. Baseline may be the same as the screening laboratory tests.  
5Safety laboratory tests include WBC  with differential, hemoglobin, platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT.  
6 Any laboratory tests performed as part of routine clinical care within the specified visit window can be used for safety labo ratory testing. Window during 
the 10 days of dosing is ±1 day.  
7 In-person visits are preferred but recognizing quarantine and othe r factors may limit the subject’s ability to return to the site for the visit. In this case, the 
visit may be performed by phone.  
• If still hospitalized at Day 15 and 29 or returns to the site for an in -person  visit: Clinical data, vital signs, safety labor atory tests, and research 
laboratory samples (OP swab and serum  only) as able.   
• If phone call only  on Days 15 and 29 and all Day 22 visits: assess adverse events, clinical status (ordinal scale), readmission to a hospital, and 
mortality only.  
8 Oropharynge al swabs are preferred, but if these are not obtainable, nasopharyngeal swabs may be substituted.  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 14 of 65  
1.3 Study Schema  
 
 
2. INTRODUCTION 
2.1 Study Rationale  
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS -CoV-2) and causes 
substantial morbidity  and mortality.  There is currently no vaccine to prevent infection with 
SARS -CoV-2 or therapeutic agent to treat COVID -19. This clinical trial is designed to evaluate 
investigational therapeutics for the treatment of adult s hospitalized with COVID -19. 
2.2 Background  
2.2.1 Purpose of Study  
Coronavirus (CoVs) are positive- sense , single stranded, enveloped RNA viruses, many of which 
are commonly found in humans and cause mild symptoms. Over the past two decades, emerging 
pathogenic CoVs capable of causing life-threatening disease in humans and animals have been identified, namely , severe acute respiratory syndrome coronavirus (SARS- CoV) in 2002-2003 
and Middle East respiratory syndrome coronavirus (MERS -CoV)  in 2012.  
 In December 2019, the Wuhan Municipal Health Committee  (Wuhan, China)  identified an 
outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been designated as SARS -COV-2 and has 89% 
nucleotide identity with bat SARS -like-CoVZXC21 and 82% with that of human SARS- CoV ( 1). 
The human disease caused by SARS -CoV-2 has been designated COVID -19. In most (~80%) 
cases, COVID -19 presents as a mild-to-moderately severe, self -limited acute respirato ry illness 
with fever, cough, and shortness of breath. Symptoms are thought to  appear 2  to 14 days after 
exposure. COVID -19 can be severe , resulting in pneumonia, severe acute respiratory syndrome, 
kidney failure, and death. The first US COVID -19 death occurred on February 29, 2020. 

Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 15 of 65  
During this COVID-19 outbreak, t he incidence of cases has rapidly increased  such that on January 
5, 2020 there were 59 confirmed cases , 278 cases on January 20, 2020, and more than 318,000 
cases and 13,000 deaths as of March 22 , 2020 according to various international health reporting 
agencies. As a result, on January 30, 2020, the International Health Regulations Emergency 
Committee of the World Health Organization (WHO) declared the COVID -19 outbreak a Public 
Health Emergency of International Concern. On January 31, 2020, the US Department of Health and Human Services declared a public health emergency in the United States. On March 11, 2020, the WHO declared the COVID -19 outbreak a pandemic.  Outbreak for ecasting and modeling 
suggest that these numbers will continue to rise (2 ).  
 Global efforts to evaluate novel antivirals and therapeutic interventions to treat COVID -19 have 
intensified. There is currently no vaccine to prevent SARS -CoV-2 infection or the rapeutic agent 
to treat COVID -19. Therefore, there is an urgent public health need for rapid development of 
novel interventions.   
2.2.2 Potential Therapeutics 
Remdesivir (GS -5734) is a broad-spectrum nucleotide prodrug that inhibits RNA-dependent 
RNA polymerase activity among a diverse group of RNA viruses including filoviruses (e.g. 
Ebola, Sudan, Marburg), paramyxoviruses (e.g., RSV, Nipah, Hendra) and pathogenic coronaviruses ( 3-5).  Multiple nonhuman primate studies demonstrated the therapeutic efficacy of 
remdesivir against Ebola virus (4, 5). Remdesivir was used in a randomized clinical trial for Ebola ( the PALM study) (6). While remdesivir was demonstrated to be inferior to investigational 
treatment with monoclonal antibodies MAb114 and REGN-E B3 in the PALM study, the lack of 
a control arm limits interpretation of the clinical efficacy of remdesivir . Studies in human airway 
epithelial cell assays demonstrated that remdesivir inhibits replication of coronaviruses, including MERS- CoV ( 7). In mouse infection models, remdesivir had therapeutic efficacy 
against SARS -CoV and ME RS-CoV ( 7,8). In vitro studies with mouse hepatitis virus ( a murine 
coronavirus) found that remdesivir inhibits coronavirus replication through interference with the viral polymerase, despite the presence of a viral proofreading exoribonuclease (9). In that study, coronaviruses that were partially resistant to inhibition by remdesivir  were still sensitive to 
higher concentrations of remdesivir, and fitness was impaired in the res istant viruses as 
compared to wild-type MERS-CoV. In a recent non-human primate study, therapeutic remdesivir treatment initiated 12 hours post inoculation with MERS -CoV provided clinical benefit with a 
reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions (10,11).  These nonclinical data suggest that remdesivir might be useful 
for the treatment of COVID -19 for which no medical countermeasures are currently approved, 
and support testing the e fficacy of remdesivir treatment in hospitalized adults with COVID -19 
(12).  
2.3 Risk/Benefit Assessment  
2.3.1 Known Potential Risks  
Potential risks of participating in this trial are those associated with having blood drawn, the IV cathete rization, possible reactions to remdesivir  (as noted in Section 2.3.2), and breach of 
confidentiality.  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 16 of 65  
Drawing blood may cause transient discomfort and fainting. Fainting is usually transient and managed by having the subject lie down and elevate his/her legs. Bruising at the blood collection sites may occur but can be prevented or lessened by applying pressure to the blood draw site for a few minutes after the blood is taken. IV catheterization may cause insertion site pain, phlebitis, 
hematoma formation, and infusate extravasation; less frequent but significant complications include bloodstream and local infections. The use of aseptic (sterile) technique will make infection at the site where blood will be drawn or at catheter site less likely.  
 Risks to Privacy Subjects will be asked to provide personal health information (PHI). All attempts will be made to keep this PHI confidential within the limits of the law. However, there is a ch ance that 
unauthorized persons will see the subject’s PHI. All study records will be kept in a locked file cabinet or maintained in a locked room at the participating clinical site. Electronic files will be password protected. Only people who are involved in the conduct, oversight, monitoring, or auditing of this trial will be allowed access to the PHI that is collected. Any publication from this trial will not use information that will identify subjects. Organizations that may inspect and/or copy research records maintained at the participating site for quality assurance and data analysis 
include groups such as the IRB, NIAID and applicable regulatory agencies (e.g., FDA). For more 
information about confidentiality and privacy see Section 10.1.3.  For each new therapeutic agent under investigation, findings from the preclinical and clinical studies will be briefly described in this section and a summary of the findings described in the Investigator Brochure (IB) will be in an appendix.  
 
2.3.2 Potential Risks of Remdesivir  
Remdesivir is an investigational therapeutic agent.  As of February 14, 2020, 138 healthy adults 
have been dosed with remdesivir in four Phase 1 clinical trials. Few subjects to date experienced  
constipation, heartburn, itching, unusual feelings in the ear, dizziness, loss of appetite, nausea, 
vomiting, shaking of the leg and arm, headache, loose stool, or upset stomach. These AEs  were 
temporary, lasting only a few days, and none were serious. In clinical studies, transient 
elevations in ALT and AST have been observed with single doses of remdesivir up to 225 mg 
and multiple once daily doses of remdesivir 150 mg for up to 14 days. M ild (Grade 1)  reversible 
PT prolongation was also noted in some subjects but without any clinically  significant change in 
INR or other evidence of hepatic effects. The mechanism of these elevations is currently unknown. Based on these clinical observations, patients with ALT or AST >5 times the upper limit of normal will not be eligible for study enroll ment. R egular laboratory assessments will be 
performed in order to monitor hepatic function and PT . Any observed liver function- related 
laboratory abnormalities or possibly related AEs will be treated appropriately and followed to resolution.   
In nonclinical animal studies, toxicity studies found dose-dependent and reversible kidney injury and dysfunction. In clinical studies, no evidence of nephrotoxicity has been observed with single doses of remdesivir up to 225 mg or multiple once daily doses of remdesivir 150 mg for up to 14 days. A 150-mg dose of the solution and lyophilized formulations of remdesivir contains 9 g and 
4.5 g, respectively, of sulfobutylether- beta- cyclodextrin  (SBECD ), for which the maximum daily 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 17 of 65 recommended daily dose (based on a European Medicines Agency ( EMA ) safety review) is 
approximately 250 mg/kg. Because SBECD is renally cleared, subjects with moderate or severe 
renal impairment may have SBECD exposures greater than those with less severe r enal 
impairment or normal renal function. Based on this information, patients with  an estimated 
glomerular filtration rate (eGFR) of less than  30 ml/min (including subjects requiring 
hemo dialysis  or hemofiltration ) will not be eligible for study enrollment. 
 Remdesivir is a substrate for CYP2C8, CYP2D6, and CYP3A4. However, coadministration with inhibitors of these CYP isoforms is unlikely to markedly increase remdesivir levels, as its metabolism is likely to be predominantly mediated by hydrolase activity.  See IB for full 
discussion of clinical experience and risks.   There is the potential of the SARS-CoV-2 developing resistance to remdesivir, which could result in decreased efficacy.  The clinical impact of the development of resistance is not clear at 
this time.  
 In vitro induction studies have demonstrated that a clinically relevant interaction with contraceptive steroids is considered to be of limited clinical significance.  Therefore,  the use of 
hormonal contraception with remdesivir is not recommended as the sole method for preventing pregnancy.  
2.3.3 Known Potential Benefits  
Remdesivir may or may not improve the clinical outcome of an individual subject with COVID -
19 who participates in this trial. However, there is potential benefit to society from their 
participation in this study resulting from insights gained about the therapeutic agent under study 
as well as the natural history of the disease. While there may not be benefits for an individual 
subject, t here may be b enefits to society  if a safe, efficacious therapeutic agent can be identified 
during this global COVID-19 outbreak.   
2.3.4 Assessment of Potential Risks and Benefits  
Remdesivir is generally a well -tolerated medication . There are liver toxicities that have been 
observed in prior studies. These have been self -limited and resolved after cessation of the 
medication.  There is the potential for renal toxicities as observed in pre -clinical data.  By excluding 
those with elevated liver transaminases and decreased kidney function ( eGFR  < 30 ml/min  or 
requires hemo dialysis  or hemofiltration ), and appropriate monitoring during the study, we can 
minimize the risk to subjects. While there may not be benefits for an individual subject, there may 
be benefits to society if a safe, efficacious therapeutic agent can be identified during this global 
COVID- 19 outbreak.  The potential risks therefore are thought to be acceptable given the potential 
benefits.  
3. OBJE CTIVES  AND  ENDPOINTS 
The overall objective of the study is to evaluate the clinical efficacy and safety of different 
investigational therapeutics relative to the control arm among  hospitalized adults who have 
COVID-19.  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 18 of 65 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
To evaluate the clinical efficacy, as assessed 
by time to recovery, of different 
investigational therapeutics as compared to the control arm. Day of recovery is defined as the first day on 
which the subject satisfies one of the following three categories from the ordinal scale:  
• Hospitalized, not requiring supplemental 
oxygen - no longer requires ongoing 
medical care;  
• Not hospitalized, limitation on activities and/or requiring home oxygen; 
• Not hospitalized, no limitations on activities.  
Recovery is evaluated up until Day 29.  
Key Secondary   
To evaluate the clinical efficacy of different 
investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8 -
point ordinal scale) at Day 15 
 
  • Death;  
• Hospitalized, on invasive mechanical 
ventilation or ECMO; 
• Hospitalized, on non- invasive ventilation 
or high flow oxygen devices; 
• Hospitalized, requiring supplemental 
oxygen; 
• Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID -19 related or otherw ise); 
• Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;  
• Not hospitalized, limitation on activities and/or requiring home oxygen; 
• Not hospitalized, no limitations on 
activities.  
Additional Secondary   
1. To evaluate the clinical efficacy of 
different investigational therapeutics as compared to the control arm as assessed by: 
• Clinical Severity  
o Ordinal scale:  
 Time to an improvement of one category and two categories from Day 1 (baseline) using an ordinal scale.   
  
• Clinical outcome assessed using ordinal scale daily while hospitalized and on Day s 
15, 22, and 29. 
   
 
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 19 of 65 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
 Subject clinical status using ordinal 
scale at Days 3, 5, 8, 11, 15, 22, and 
29.  
 Mean change in the ordinal scale from Day 1 to Days 3, 5, 8, 11, 15, 22, and 29. 
  
 
o National Early Warning Score 
(NEWS):  
 Time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.  
 Change from Day 1 to Days 3, 5, 8, 11, 15, and 29 in NEWS.  
  
 
• NEWS assessed daily while hospitalized 
and on Days 15 and 29. 
o Oxygenation:  
 Oxygenation use up to Day 29. 
 Incidence and duration of new 
oxygen use during the study. 
  
• Days of supplemental oxygen (if 
applicable) up to Day 29 
 
o Non-invasive ventilation/high flow 
oxygen: 
 Non-invasive ventilation/high flow 
oxygen use up to Day 29. 
 Incidence and duration of new non-
invasive ventilation or high flow oxygen use during the study. 
 • Days of non -invasive ventilation /high 
flow oxygen (if applicable)  up to Day 29 
o Invasive Mechanical Ventilation / 
extracorporeal membrane oxygenation (ECMO):  
 Ventilator / ECMO use up to Day 
29. 
 Incidence and duration of new mechanical ventilation o r ECMO use 
during the study.  
  
• Days of invasive mechanical ventilation /ECMO (if applicable)  up to 
Day 29. 
 
• Hospitalization  
o Duration of hospitalization (days).  
  
• Days of hospitalization up to Day 29 
• Mortality  
o 14-day mortality  
o 29-day mortality  
  
• Date and cause of death (if applicable)  
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 20 of 65 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
2. To evaluate the safety of different 
investigational therapeutics as compared to 
the control arm as assessed by:  
• Cumulative incidence of SAEs through Day 29. 
• Cumulative incidence of Grade 3 and 4 
clinical and/or labor atory AEs through 
Day 29. 
• Discontinuation or temporary 
suspension of infusions (for any reason) 
• Changes in white blood cell (WBC) count with differential, hemoglobin, platelets, creatinine, glucose, total bilirubin, alanine aminotransferase (ALT), aspartat e aminotransferase 
(AST), and prothrombin time (PT) over time (analysis of lab values in addition 
to AEs noted above).   
  
• SAEs  
• Grade 3 and 4 AEs  
• WBC  with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT on Day 1; Days 3, 5, 8, and 11 (while hospitalized); and Days 15 and 29 (if attends in-person visit or still hospitalized) . 
 
Exploratory   
To evaluate the virologic efficacy of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Percent of subjects with SARS-CoV-2 detectable in OP sample at Days 3, 5, 8, 11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in OP 
sample at Days 3, 5, 8, 11, 15, and 29. 
• Development of resistance of SARS-
CoV-2 in OP sample at Days 3, 5, 8, 
11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in 
blood at Days 3, 5, 8, and 11. 
  
 
 
• Qualitative and quantitative polymerase 
chain reaction (PCR) for SARS -CoV-2 in 
OP swab on Day 1; Days 3, 5, 8, and 11 
(while hospitalized); and Days 15 and 29 
(if attends in -person visit or still 
hospitalized). 
• Qualitative and quantitative PCR for 
SARS -CoV-2 in blood on Day 1; Days 3, 
5, 8, and 11 (while hospitalized). 
  
4. STUDY  DESIGN 
4.1 Overall Design  
This study is an adaptive, randomized, double-blind, placebo- controlled trial to evaluate the 
safety and efficacy of novel therapeutic agents in hospitalized ad ults diagnosed with COVID-19. 
The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to allow  early stopping for futility, efficacy, or safety. If one therapy 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 21 of 65 proves to be efficacious, then this treatment may become the control arm for comparison(s) with 
new experimental treatment(s). Any such change would be accompanied by an updated sample size. Because background standards of supportive care may evolve/improve over time as more is 
learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms.   The initial sample size is projected to be 572 subjects to achieve 400 subjects with a “ recovered” 
status (per  the primary objective) . The primary analysis will be based on those subjects enrolled 
in order to 400 recoveries.  An additional analysis of the moderate severity subgroup (those with baseline status of “Hospitalized, requiring supplemental oxygen” or “Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care”)  is also of public health importance. Hence, enrollment will be permitted until the date of April 20, 2020 to ensure 400 recoveries and provide additional data about this important subgroup. With recent enrollment rates, the total sample size may be 600 to over 800.   If any additional therapeutic arms are added, the sample size will be recalculated.  
 Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subje cts, i t is 
preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and OP 
swab and blood (serum only) samples for secondary research  as well as clinical outcome data. 
However , infection control or other restrictions may limi t the ability of the subject to return to 
the clinic.  In this case, these visits may be conducted by phone, and only clinical data will be 
obtained. The Day 22 visit does not have laboratory tests or collection of samples  and may also 
be conducted by phone.   The primary outcome is time to recovery by Day 29 (see table below for definition based on the ordinal scale).  A key secondary outcome evaluates treatment- related improvements in the 8 -point 
ordinal scale at Day 15. As little is known about the clinical course of COVID -19, a n evaluation 
of the pooled (i.e., blinded to treatment assignment) proportion recovered will be used to gauge whether the targeted total number of subjects in the recovered categories of the ordinal scale will 
be achieved  with  a planned sample size of 572 .  The primary analysis will include data from both 
severity groups using a stratified log- rank test.  The analysis of the pilot data will be blinded, 
allowing for the pilot data to be included in subsequent analyses.   The study will randomize subjects 1:1 to placebo or investigational product. In the absence of an 
established treatment, the use of placebo is justified. If additional arms are added to or dropped 
from the trial, randomization will proceed with an equal probability of assignment to each of the remaining arms. Randomization will be stratified  by site and severity  (severe versus mild -
moderate).  See Section 6.3 for more information on randomization and stratification. 
4.2 Scientific Rationale for Study Design  
At present, there is no specific ant iviral therapy for coronavirus infections. Few treatment studies 
have been conducted because most human coronavirus strains cause self- limited disease and care 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 22 of 65 is supportive. After the SARS -CoV was identified in 2002-2003 and caused a large global 
outbreak, there was an increased interest in the development of specific therapeutic agent s. 
SARS -CoV patients were treated with corticosteroids, type 1 IFN agents, convalescent plasma, 
ribavirin, and lopinavir or ritonavir, and except for ribavirin, many of these agents have in vitro 
pre-clinical data that support their efficacy ( 13-28). Since the SARS -CoV outbreak in 2002-
2003, new therapeutic agents targeting viral entry proteins, proteases, polymerases, and methyltransferases have been tested ; however, none of them has been shown to be efficacious in 
clinical trials ( 29-31).   
 This study utilizes an adaptive design that increase s efficiency to identify safe and efficacious 
therapeutic agent s for patients with COVID -19 during the current outbreak. Some investigational 
products may be in limited supply and this study design enables continuation of the study even if a product becomes unavailable. In addition, the adaptive design allows for the evaluation of new therapeutic agents as they are identified and ready for testing in clinical trials . As the study is  a 
multicenter, multinational randomized controlled study, we will be able to acquire rigor ous data 
about the safety and efficacy of investigational therapeutic agents for COVID- 19 that will lead to 
generalizable evidence. Randomization is essential for establishing efficacy of these new therapeutic agents. Last, collecting clinical and virologic data on enrolled subjects  using a 
standardized timeline and collection instruments should provide valuable information about the clinical course of and morbidities associated with COVID -19 in a diverse group of hospitalized 
adults.  
4.3 Justification for Dos e 
The dose of remdesivir  used in this study will be the same dose that was used in the Ebola 
clinical trials.  
 
5. STUDY  POPULATION  
Approximately 572 male and non-pregnant female adults ≥18 years of age or older w ith COVID -
19 and who  meet all eligibility criteria will be enrolled at up to  approximately 100 c linical trial 
sites globally. The target population should reflect the community at large. The estimated time from screening (Day - 1 or Day  1) to end of study for an individual subject is approximately 29 
days.   Subject Inclusion and Exclusion Criteria must be confirmed by any clinician named on the delegation log. If there is any uncertainty, the PI should make the decision on whether a potential subject is eligible for study enrollment. There is no exclusion for receipt of SARS-CoV-2 vaccine (experimental or licensed).  
 
5.1 Inclusion Criteria  
In order to be eligible to participate in this study, a patient  must meet all of the following criteria:  
1. Admitted to a hospital with symptoms suggestive of COVID-19 infection. 
2. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 23 of 65 3. Subject (or legally authorized representative ) understands and agrees to comply with 
planned study procedures. 
4. Male or non-pregnant female adult ≥18 years of age at time of enrollment. 
5. Has laboratory -confirmed SARS -CoV-2 infection as determined by PCR or other 
commercial or public health assay in any specimen, as documented by either of the 
following:  
• PCR positive in sample collected < 72 hours prior to randomization; OR 
• PCR positive in sample collected ≥ 72 hours prior to randomization, documented 
inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc.). AND progressive disease suggestive of ongoing SARS-CoV-2 infection. 
6. Illness of any duration, and at least one of the following: 
• Radiographic infiltrates by imaging (chest x- ray, CT scan, etc.), OR  
• SpO2 ≤ 94% on room air, OR 
• Requiring supplemental oxygen, OR 
• Requiring mechanical ventilation. 
7. Women of childbearing potential must agree to either abstinence or use at least one 
primary form of contraception not including hormonal contraception from the time of screening through Day 29.  
8. Agrees to not participate in another clinical trial for the treatment of COVID -19 or 
SARS -CoV-2 through Day 29. 
 
5.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study: 
1. ALT  or AST > 5 times the upper limit of normal.  
2. Estimated glomerular filtration rate (eGFR ) < 30  ml/min  (including patients receiving 
hemodialysis or hemofiltration).  
3. Pregnancy or breast feeding. 
4. Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours. 
5. Allergy to any study medication. 
 
5.2.1 Exclusion of Spec ific Populations  
Children and adolescents will not be included in this trial. Remdesivir has only been used in a 
small number of pediatric patients. Initial information about the epidemiology of COVID -19 
indicates that the overwhelming burden of severe disease occurs among older adults, especially 
those with comorbidities.  Given significant gaps in knowledge in this population, and a low 
incidence of severe morbidity/mortality in children, the risk/benefits do not warrant inclusion of 
this population into this trial at this time.  
 In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryo-fetal development when administered to pregnant animals. Embryonic toxicity was seen 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 24 of 65 when remdesivir was initiated in female animals prior to mating and conception, but only at a 
system ically toxic dose. Remdesivir has not been studied in pregnant women. Because the 
effects on the fetus and the pregnant woman are not fully known, pregnant women will not be 
eligible for the trial.  
 In animal studies, remdesivir metabolites have been detected in the nursing pups of mothers given remdesivir. It is not known whether remdesivir is secreted in human milk. Because the effects of re mdesivir on the breastfeeding infant is not known, women who are breast feeding 
will not be eligible for the trial.  
 
5.3 Inclusion of Vulnerable Subjects  
Certain human subjects are categorized as vulnerable populations and require special treatment with respect to safeguards of their well -being. For this clinical trial, examples include cognitively 
impaired or mentally disabled persons and intubated individuals who are sedated.  When it is 
determined that a potential research subject is cognitively impaired, federal and institutional 
regulations permit researchers to obtain consent from a legally authorized  representative (LAR). 
The study team will obtain consent from these vulnerable subjects using an IRB-approved protocol- specific process for consent using a LAR.  For subjects for whom a LAR gave consent, during the course of the study, if the subject regains the capacity to consent, informed consent must be obtained from the subject and the subject offered the ability to leave the study if desired. 
5.4 Lifestyle Considerations  
During this study, subjects are asked to: 
• Refrain from drinking alcohol through Day 15.  
• Avoid taking paracetamol (acetaminophen) through Day 15. (Other non- steroidal anti-
inflammatory drugs or antipyretic drugs are acceptable) . 
• Avoid getting pregnant during the study from Day 1 through Day 29. 
• Avoid participation in another clinical trial for the treatment of COVID -19 or SARS -
CoV-2. Co -enrollment for natural history studies of COVID-19 or SARS-CoV-2 is 
permitted ; however, participation in both ACTT and natural history studies can only 
occur if the recommended blood collection volumes are not exceeded.  
5.5 Screen Failures  
Following consent, after the screening evaluations have been completed, the investigator or 
designee is to review the inclusion/exclusion criteria and determine the subject’s eligibility for the study. If there is any uncertainty, the PI should make the decision on whether a potential subject is eligible for study enrollment.   Only basic demographic information and the reason (s) for ineligibility will be collected on 
screen failures . Subjects who are found to be ineligible will be told the reason(s) for ineligibility.  
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 25 of 65 Individuals who do not meet the criteria for participation in this study (screen failure) because of 
an abnormal laboratory finding may be rescreened once. 
5.6 Strategies f or Recruitment and Retention 
5.6.1 Recruitment  
It is anticipated that patients with COVID -19 will present to participating hospitals, and that no 
external recruitment efforts towards potential subjects are needed.  Recruitment efforts may also 
include dissemination of information about this trial to other medical professionals / hospitals.   
 The IRB will approve the recruitment process and all materials provided prior to any recruitment 
to prospective subjects directly.  Screening will begin with a brief discussion with study staff. Some will be excluded based on demographic data and medical history ( i.e., pregnant, < 18 years of age, renal failure, etc.). 
Information about the study will be presented to potential subjects  (or legally authorized 
representative)  and questions will be asked to determine potential eligibility. Screening 
procedures can begin only after informed consent is obtained.  
5.6.2 Retention  
Retention of subjects in this trial is very important for determining the primary endpoint. As 
such, after hospital discharge, participating subjects will be reminded of subsequent study visits  
and every effort will be made to accommodate the subject’s schedule to facilitate follow -up 
within the specified visit window . Additionally, there are many circumstances that influence the 
ability to obtain outcome information after discharge. Follow-up visits may be conducted by 
phone if in-person visits are not feasible.  
5.6.3 Compensation Plan for Subjects  
Compensation, if any, will be determined locally and i n accordance with local IRB requirements, 
and subject to local IRB approval.  
 
5.6.4 Costs  
There is no cost to subjects for the research tests, procedures/evaluations and study product while 
taking part in this trial. Procedures and treatment for clinical care including costs associated with hospital stay may be billed to the subject, subject’s insurance or third party.  
6. STUDY  PRODUCT 
6.1 Study Product(s) and Administration  – GS-5734 ( Remdesivir ) and 
placebo  
6.1.1 Study Product Description  
Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular 
delivery of a modified adenine nucleoside analog GS-441524. In addition to the active 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 26 of 65 ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: 
water for injection, SBECD, and hydrochloric acid and/or sodium hydroxide. 
 The supplied matching placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, due to limitations on placebo supplies, normal saline may  be given at an equal volume as a placebo in 
place of the lyophilized formulation.  
6.1.2 Dosing and Administration 
Subjects will be randomized 1:1 to receive either active product or placebo. Initially, the trial 
will have 2 arms:  
• Remdesivir will be administered as a 200 mg IV loading dose on Day 1, followed by a 
100 mg once-daily IV maintenance dose while hospitalized for  up to a 10 day total 
course.  If a subject is no longer hospitalized, then infusions will no longer be given.  
o The total course should not exceed 10 calendar days even if an infusion was 
missed.  
• A matching placebo will be given at an equal volume at the same schedule.   
 The dose should be given the same time each day (+/ - 2 hours for medication scheduling). 
 Any dose that is delayed may be given later that calendar day . Any dose that is missed (not given 
that calendar day) is not made up. The treatment course continues as described ab ove even if the 
subject becomes PCR negative.   
 
6.1.3 Dose Escalation 
Not Applicable 
 
6.1.4 Dose Modifications 
There are no clinical safety or pharmacokinetic data available for remdesivir  in patients with 
renal and/or hepatic impairment. Given the benefit- to-risk ratio in patients with COVID -19, these 
subjects are excluded from the study.  
 If the eGFR  decreases to  an eGFR < 25 ml/min , the study infusion should not be given on that 
day. The infusion may be resumed on the next day if the eGFR  returns to ≥ 30 ml/min . If the 
subject’s renal function worsens to the point that they require hemo dialysis  or hemofiltration , 
study product will be discontinued.  If the ALT and/or AST increases to > 5 times upper limits of normal, the dose of remdesivir 
should be held and not be restarted  until the ALT and AST ≤ 5 times upper limits of normal. 
 
6.1.5 Overdosage 
There is no known antidote for remdesivir. In the case of overdose, the subject should receive 
supportive therapy based on the subject´s signs and symptoms. 
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 27 of 65 6.2 Preparation/Handling/Storage/Accountability  
6.2.1 Acquisition and Accountability  
Investigational products (IP) will be shipped to the site either directly from participating 
companies , from the Sponsor, or from other regional or local drug repositories. All other supplies 
should be provided by the site. Multiple lots of each IP may be supplied.  Study products received at the sites will be open label and not kit specific , unless specified  in the 
protocol- specific Manual of Procedures (MOP) . Drug preparation will be performed by the 
participating site’s research pharmacist on the same day of administration to the subject. See the MOP  Appendices for detailed information on the preparation, labeling, storage, and 
administration of remdesivir and placebo.   
Accountability: 
The site PI is responsible for study product distribution and disposition and has ultimate responsibility for study product accountability. The site PI may delegate to the participating site’s research pharmacist responsibility for study product accountability. The participating site’s research pharmacist will be responsible for maintaining complete records and documentation of study product receipt, accountability, dispensation, storage conditions, and final disposition of the study product(s). Time of study drug administration to the subject will be recorded on the appropriate data collection form ( CRF ). All study product(s), whether administered or not, must 
be documented on the appropriate study product accountability record or dispensing log. The Sponsor ’s monitoring staff will verify the participating site’s study product accountability 
records and dispensing logs per the site monitoring plan. Refer to the protocol- specific MOP for 
details on storing study medications.  
Destruction:  
After the study treatment period has ended or as appropriate over the course of the study after 
study product accountability has been per formed, used active and placebo vials can be destroyed 
on-site following applicable site procedures with a second staff  member  observing and verifying 
the destruction.  
Unused vials at the end of the study should be saved until instructed by the Sponsor. 
 
6.2.2 Formulation, Appearance, Packaging, and Labeling 
Product: Remdesivir  
The lyophilized formulation of remdesivir  is a preservative- free, white to off- white or yellow,  
lyophilized solid containing 150 mg or 100 mg of remdesivir to be reconstituted with 29 mL or 
19 mL (respectively) of sterile water  for injection respectively and diluted into IV infusion fluids 
prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL remdesivir concentrated solution with sufficient volume to allow withdrawal of 30 mL (150 mg of remdesivir)  or 20 mL (100 mg of remdesivir).  
 It is supplied as a sterile product in a single- use, Type 1 clear glass vial. In addition to the active 
ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 28 of 65 water for injection, SBECD, hydrochloric acid, and/or sodium hydroxide. For more information, 
refer to the MOP.  
 
Placebo:  
The supplied matching placebo lyophilized formulation, 150 mg or 100 mg equivalent, is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. The lyophilized formulation of matching placebo is filled in a Type 1 clear glass vial closed with a  rubber stopper and aluminum seal with a plastic flip -off cap. Each single-
use vial contains sufficient volume to allow withdrawal of 30 mL or 20 mL of placebo following reconstitution.  Alternatively, due to limitations on placebo supplies, a matching placebo of normal saline may  
be given at an equal volume at the same schedule.  In this case, IV bags of study treatment (both 
the Active and the Placebo) will be covered to mask the slight color difference between the remdesivir solution and placebo to maintain the study blind.   Each of the study products will be labeled according to manufacturer specifications and include the statement “Caution: New Drug Limited by Federal Law to Investigational Use.”  
 
6.2.3 Product Storage and Stability  
Product: Remdesivir  
Ambient vials of the lyophilized formulation of remdesivir should be stored below 30°C. The 
lyophilized formulation needs to be reconstituted and then diluted into IV infusion fluids before use. After reconstitution, the total storage time before completion of admin istration (including 
any time before or after dilution) should not exceed 4 hours at room temperature (20°C to 25°C) or 24 hours at refrigerated temperature (2°C to 8°C).  See MOP for additional information.  
 
Placebo:  
Vials of the lyophilized formulation of matching placebo should be stored below 30°C. The lyophilized formulation needs to be reconstituted and then diluted into IV infusion fluids before use. After reconstitution, the total storage time before completion of administration (including any time  before or after dilution) should not exceed 4 hours at room temperature (20°C to 25°C) 
or 24 hours at refrigerated temperature (2°C to 8°C).  
 If used, the saline placebo should be kept under the same conditions as the matching lyophilized placebo, in order to maintain the blind.  
6.2.4 Preparation  
Refer to the protocol-specific MOP for details about preparation.  
 
Remdesivir does not meet the criteria for a hazardous compound as defined by NISOH and 
ASHP hazard classification systems.  The study products may be prepared in a clean room but do 
not need to be prepared or handled in a fume hood. 
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 29 of 65 Measures that minimize drug contact with the body should always be considered during 
handling, preparation, and disposal procedures as indicated in the IB .  
6.3 Measures to Minimize Bias: Randomization and Blinding 
The study will randomize subjects  1:1 to placebo or investigational product. If additional arms 
are added to or dropped from the trial, randomization will proceed with an equal probability of assignment to each of the remaining arms.  Randomization will be stratified  by: 
• Site 
• Severity of illness at enrollment:  
o Severe disease: requiring mechanical ventilation , requiring oxygen, a SpO2 ≤ 94% 
on room air, or tachypnea (respiratory rate ≥ 24 breaths/min). 
o Mild -moderate disease: SpO2 > 94% and respiratory rate < 24 breaths/min without 
supplemental oxygen.  
 The randomization procedure will be described in the MOP.   
6.4 Study Intervention Compliance  
Each dose of study product will be administered by a member of t he clinical research team who 
is qualified and licensed to administer the study product. Administration and date, and  time, will 
be entered into the case report form (CRF).  
 
6.5 Concomitant Therapy  
Therapy prior to enrollment with any other experimental treatm ent or off- label use of marketed 
medications that are intended as specific treatment for COVID -19 or the SARS-CoV-2 infection 
(i.e., post-exposure prophylaxis [PEP]) are permitted but must be discontinued on enrollment. 
There is no waiting period between discontinuation of these treatments and infusion of study 
product. However, these prior treatments and their end date should be documented on the 
Concomitant Medication (CCM) form.  
 
Subject s who are taking another antiviral for a concurrent infect ion (e.g. oseltamivir for an 
influenza virus, lopinavir/ritonavir for HIV, etc.) or immunosuppressive drugs for other medical conditions (tocilizumab for rheumatoid arthritis, hydroxychloroquine for lupus, etc.) may  
continue with the treatment.   
 
A subject  cannot participate in another clinical trial for the treatment of COVID -19 until after  Day 
29 (s ee exclusion criteria) .  
 
If the local standard of care per written policies or guidelines for treatment for COVID -19 or 
SARS -CoV-2 infection (i.e. , not just an individual clinician decision) includes lopinavir/ritonavir 
(Kaletra) , hydroxychloroquine or other agents (e.g. those targeting the host immune response), 
then continuing these during the study is permitted, but may require additional safety monitoring 
as determined by the treating clinician . Additionally, there should be plans on how the 
concomitant drugs are stopped for additive toxicities (Section 6.1.4).  If the re are NO written 
policies or guidelines for local standard of care,  concomitant use of any other experimental 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 30 of 65 treatment or off-label use of marketed medications intended as specific treatment for COVID -19 
or SARS -CoV-2 infection are prohibited. This includes medications that target the host immune 
response.  
 
No clinical drug-drug interaction (DDI) studies have been conducted w ith remdesivir . Final 
guidance about the drug and possible DDI should come from the IB and the protocol. Site PIs 
should review the prescription drugs that the subject is getting for pre-existing comorbidi ties and 
determine if these agents may lead  to antagonism or synergy with remdesivir and modify safety 
monitoring accordingly. 
 
There is no available data on potential interactions between remdesivir and other anti -SARS -
CoV investigational agents. Administering remdesivir concurrently with other agents may lead to antagonism or synergy or may have no effect.   Concomitant medications will be assessed only from 7 days prior to enrollment to Day 11 or 
upon discharge, whichever comes first. Concomitant medications should be reported on the designated CRF. Report all prescription medications taken during this time period. Do not report vitamins, herbal supplements, or topical medications. Do not report over- the-counter cold 
medicines and antipyretics that the subject reportedly took at home prior to hospitalization. 
Record all antipyretics and other medications given for symptomatic care, if they are 
administered while an inpatient.  However, record these medications only once, even if given 
multiple times , as needed during hospital course.  
 Of note, acetaminophen is prohibited during the study through Day 15, even if clinically indicated for a subject. Acetaminophen should not be used because of the concerns of additive hepatotoxicity with  active product. Other antipyretics and/or analgesics that are not hepatotoxic 
may be used, such as NSAIDS.  
6.5.1 Rescue Medicin e 
Not Applicable 
 
6.5.2 Non-Research Standard of Care  
Not Applicable 
 
7. STUDY  INTERVENTION  DISCONTINUATION  AND  
SUBJECT  DISCONTINUATION/WITHDRAWAL 
7.1 Halting Criteria and Discontinuation of Study Intervention  
7.1.1 Individual Infusion Halting  
See Section 6.1.4. for information about dosing modifications due to laboratory abnormalities. 
For an individual subject, an individual infusion must be stopped if they have a suspected drug -
related event of hypersensitivity (Grade 2 or higher) during the infusion. While there are no criteria 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 31 of 65 for grading “hypersensitivity” in the Division of AIDS (DAIDS) Table for Grading the Severity 
of Adverse Events, sites should use acute allergic reaction from that toxicity table.  Subjects who 
have an IV infusion stopped for a safety related issues will not continue with dosing.  
The treatment of any given subject may be stopped for  SAE s, clinically significant adverse event s, 
severe labor atory abnormalit ies, or any other medical conditions that indicate to the Investigator 
that continued dosing is not in the best interest of the patient. In addition, a subject  in this clinical study may discontinue study drug at their request for any 
reaso n. Every effort should be made to encourage subjects to remain in the study for the duration 
of their planned outcome assessments. Subjects should be educated on the continued scientific 
importance of their data, even if they discontinue study drug.  
Unles s the subject withdraws consent, those who discontinue study drug early will remain in the 
study. The reason for subject  discontinuation of study drug should be documented in the case 
report form.  
7.1.2 Study Halting  
Given the potential severity of COVID-19, there are no pre- specified study stopping rules. 
Instead there will be close oversight by the protocol team and frequent DSMB reviews of the 
safety  data.  
 
7.2 Withdrawal from  the Study  
Subjects  are free to withdraw from participation in the study at any time upon request, without 
any consequence. Subjects should be listed as having withdrawn consent only when they no longer wish to participate in the study and no longer authorize the I nvestigators to make efforts 
to continue to obtain their outcome data.   Subjects who withdraw from this study or are lost to follow-up after signing the informed consent form (ICF) and administration of the study product, will not be replaced.  The reason for 
subject withdrawal from the study will be recorded on the appropriate CRF . 
7.3 Lost to Follow -Up 
A subject will be considered lost to follow-up if he or she fails to appear for a ll follow-up 
assessment s. In lost to follow-up cases, attempts to contact the subject should be made and these 
efforts should be documented in the subject’s records.  
8. STUDY  ASSESSMENTS  AND  PROCEDURES 
8.1 Screening and Efficacy Assessments  
8.1.1 Screening Procedures  
Screening procedures may be done over one to two calendar days (from Day -1 to Day 1). However, in many cases all t he screening assessments can be done in less than 24 hours. If that is 
the case, Day 1 pre-infusion baseline assessments, specimen collection and the initial infusion can occur on the same calendar day as the screening procedures.   
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 32 of 65  
After the informed cons ent, the following assessments are performed to determine eligibility and 
obtain baseline data: 
• Confirm the positive SARS-CoV- 2 test result (per inclusion criteria) .  
• Take a f ocused medical  history , including the following information:  
• Day of onset of COVID-19 signs and symptoms. 
• History of chronic medical conditions including chronic oxygen requirement prior to onset of COVID-19. 
• History of m edication allergies . 
• Medications and therapies for this current illnes s taken in the 7 days prior to Day 1. 
• Ask if they are participating in another clinical trial or plan to enroll in another clinical trial in the next 30 days . 
• Women of childbearing potential should be counseled to either practice abstinence or use at 
least one primary form of contraception not including hormonal contraception from the time 
of screening through Day 29. Women should be confirmed to not be breastfeeding. 
• Note: If a wom an is either postmenopausal (i.e., has had ≥12 months of spontaneous 
amenorrhea) or s urgically sterile (i.e., has had a hysterectomy, bilateral ovariectomy 
(oophorectomy), or bilateral tubal ligation), she is not considered to be of 
childbearing potential.  
• Height and weight (height can be self -reported) . 
• Results of recent radiographic imaging (x- ray or CT scan) . 
• SpO2 . 
• Blood for screening laboratory evaluations if not done as part of routine clinical care in the 
preceding 48 hours: 
 ALT . 
 AST . 
 Creatinine  (and calculate eGFR ).  
• Any automated calculation by the clinical laboratory or published formula for this calculation is acceptable.  The site should select a formula to be used for all 
subjects enrolled at the site for the duration of the study. 
• Urine or s erum pregnancy test (in women of childbearing potential). 
 
Clinical screening laboratory evaluations will be performed locally by the site laboratory. The 
volume of venous blood to be collected is presented in Table 3. 
 The overall eligibility of the subject to participate in the study will be assessed once all screening values are available.  Complete the Eligibility Checklist on day of enrollment as this form 
includes data needed to register all potential subjects in the Advantage eClinical system. The 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 33 of 65 screening process can be suspended prior to complete assessment at any time if exclusions are 
identified  by the study team. 
 Study subjects who qualify will be randomized in the Advantage eClinical system, and all others will be registered as screen failures . The study team has 24 hours to complete Day 1 baseline 
assessments prior to the first infusion inclu ding the collection of OP swab and blood, assessment 
of the ordinal scale and NEWS  and completing or recording a baseline physical examination that 
was done. 
8.1.2 Efficacy Assessments  
For all baseline assessments and follow-up visits, refer to the Schedule of Assessments (SOA) 
for procedure to be done, and details below for each assessment. 
 
8.1.2.1 Measures of clinical support , limitations and infection control 
The subject’s clinical status will be captured on each study day while hospitalized and on Day 15 
and 29 if hospitalized or the subject returns for an in- person clinic visit . It will also be captured on 
Day 22 during a phone visit. Clinical status is largely measured by the ordinal scale and the NEWS. 
Unlike the NEWS, the ordinal scale can also be evaluated over the phone if the discharged subject 
is unable to return for visits on Day 15 and 29 as well as on Day 22.   Ideally, complete the ordinal scale concur rently with the NEW Score just prior to infusion, as time 
permits.  The following measures are recorded  for the ordinal scale: 
• Hospitalization . 
• Oxygen requirement. 
• Non-invasive mechanical ventilation (via mask)  requirement. 
• High flow oxygen requirement . 
• Invasive mechanical ventilation  (via endotracheal tube or tracheostomy tube) 
requirement . 
• ECMO requirement . 
• Ongoing medical care preventing hospital discharge (COVID -19 related or other medical 
conditions). 
• Limitations of physical activity (s elf-assessed).  
• Isolated for infection control purposes.  
8.1.2.2 Ordinal Scale  
 The ordinal scale is the primary measure of clinical outcome.  
 The scale used in this study is as follows  (from worst to best): 
• Death;  
• Hospitalized, on invasive mechanical ventilation or ECMO; 
• Hospitalized, on non-invasive ventilation or high flow oxygen devices; 
• Hospitalized, requiring supplemental oxygen; 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 34 of 65 • Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care 
(COVID -19 related or otherwise);  
• Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;  
o This would include those kept in hospital for quarantine/infection control, awaiting bed in rehabilitation facility or homecare, etc.  
• Not hospitalized, limitation on activities and/or requiring home oxygen; 
• Not hospitalized, no limitations on activities  
 To determine a subject’s clinical status using  the ordinal scale: On Day 1, report the ir clinical 
status at randomization. On Day 2, report the period from randomization to midnight on Day 1. On Day 3 through Day 11, or until discharged, and on Days 15, 22 and 29, provide the worst clinical assessment for the previous day (i.e., midnight to midnight; 00:00 – 23:59 (24- hr clock)). 
For example, on study Day 3  when completing the  form,  the worse clinical outcome measure of 
Day 2 is captured with the worst being death followed by ECMO, mechanical ventilation, etc. The Day 2 measurement is assessed as occurring anytime in that 24-hour period (00:00 to 23:59).  
8.1.2.3 National Early War ning Score (NEWS)  
NEWS  has demonstrated an ability to discriminate subject s at risk of poor outcomes. (Smith, 
2016). This score is based on 7 clinical parameters (see Table 2). The NEWS is being used as an 
efficacy measure. The NEW Score should be evaluated daily while hospitalized and on Days 15 
and 29. It can be perform ed concurrently with the Ordinal Scale. This should be evaluated at a 
consistent time for each  study day and prior to administration of study product. The 7 parameters 
can be obtained from the hospital chart or electronic medical record (EMR) using the last 
measurement prior to the time of assessmen t and a numeric score is given for each parameter 
(e.g., a RR of 9 is one point, oxygen saturation of 92 is two points). This is recorded for the day 
obtained ( i.e., on Day 3, the vital signs and other parameters  from Day 3 are used to obtain NEW 
Score for Day 3 ). 
 Table 2. National Early Warning Score (NEWS) 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 35 of 65  
  Level of consciousness = alert (A), and arousable only to voice (V) or pain (P), and 
unresponsive (U).  
 
8.1.3  Exploratory assessments 
8.1.3.1 Viral Load and/or Shedding  
As outlined on the SOA, OP swabs and plasma and serum will be collected on Day 1 ; and Days 
3, 5, 8, and 11 (while hospitalized); and OP swabs and serum on Day 15 and 29 ( if attends an in- 
person visit or still hospitalized ). Samples are stor ed as outlined in the MOP.  These assays are 
not developed yet, and the ability to test samples at one central lab is not clear. Therefore,  while 
viral load/shedding is thought to be an important endpoint, considering the limitations  above, it is 
listed as an exploratory endpoint.  
 OP swabs are preferred, but if these are not obtainable, nasopharyngeal (NP) swabs may be 
substituted. Due to limited lack of swabs and other supplies at some sites and limitation s on 
personal prote ctive equipment  (PPE), the inability to obtain these samples are not considered 
protocol deviations and should be documented in the subject’s record.   If virology assays can be set up with enough numbers of specimens tested, these data will be 
submitted as part of the Clinical Study Report (CSR) . This may be submitted separately, as a 
supplemental C SR.  
 Samples collected for viral assessment may be probed for the emergence of antiviral resistance at a future date.  These data, if av ailable, may be submitted as a supplement report.  
 
The schedule of assessments ( SOA, Section 1.2) lists several research laboratory samples.  It is 
preferred that the se samples are collected and sent to the NIAID repository to be tested in one 
central laboratory.  Current US Centers for Disease Control and Prevention (CDC) guidance is 
these samples can be processed in a Biosafety Laboratory (BSL) 2 environment. However, 
institutions may impose restrictions on processing the samples (i.e., they may require BSL -3) or 
there may be restrictions on sending samples. In these circumstances, the following apply: 

Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 36 of 65  
Blood for PCR SARS -CoV-2 
• If the samples can be processed but cannot be sent to the repository, the samples may be 
stored locally.  
• The sponsor may elect to have some or all of these samples run locally, pending confirmation of the assays to be used and the qualifications of the local laboratory. The 
sponsor will work with the site to determine when  this could occur and how these data can 
be imported into the study database.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted.   
 Oropharyngeal swab 
• If the samples  can be processed but cannot be sent to the repository, the samples may be 
stored locally.  
• The sponsor may elect to have some or all of these samples run locally, pending confirmation of the assays to be used and the qualifications of the local laboratory. The 
sponsor will work with the site to determine when  this could occur and how these data can 
be imported into the study database.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitte d.  
 Blood for serum (for secondary research)  
• If the samples can be processed and but not sent to the repository, the samples may be stored locally.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted .  
 
8.1.3.2 Alternative Ordinal Scales  
Given the limited clinical data available for COVID -19, the best construct of ordinal scale is not 
known. Additional data may be used to construct different ordinal scales to test their utility in a treatment study.  These are hypothesis generating and will not be submitted as part of a final 
CSR. 
 
8.2 Safety and Other Assessments  
Study procedures are specified in the SOA. A study physician licensed to make medical diagnoses and listed on the 1572 will be responsible for all trial- related medical decisions.  
 
Physical examination :  
A targeted physical examination will be performed at baseline prior to initial infusion  on Day 1. 
The baseline physical examination can be one that is conducted from screening to Day 1. Post-baseline physical examinations will be done only when needed to evaluate possible adverse 
event (s) (i.e. any new signs or symptoms). No routine physical exam is needed for stu dy visits  
after Day 1 .  
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 37 of 65 Study staff at some sites are not allowed into the subject’s rooms due to a limited supply of PPE 
and the need for strict respiratory isolation measures for COVID-19 patients. Because of limited access to subjects , physical exams can be performed by any licensed provider at the study 
hospital even if they are not study staff listed on the 1572. The study team can extract information  from the hospital chart or EMR.  
 
Clinical laboratory evaluations : 
• Fasting is not required before collection of laboratory samples. 
• Blood will be collected at the time points indicated in the SOA.   
• Clinical safety laboratory tests  include WBC, differential, Hgb, PLT, c reatinine, 
glucose, total bilirubin, AST, ALT , and PT.  Sites that do not have access to a test 
for PT will be allowed to report an international normalized ratio (INR) . 
• Day 1 clinical laboratory evaluations are drawn prior to initial infusion as a 
baseline and results do not need to be reviewed  to determine if initial infusion 
should be given. 
• Clinical laboratory testing will be performed at each clinical trial site in real time.   
 
  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 38 of 65 Table 3. Venipuncture Volumes1 
 Screen  Baseline        
Day +/ - Window  −1 to 1  1 ± 1 3 ± 1 5 ±1 8 ± 1  11 ± 1  15 ± 2 29 ± 3  
Safety hematology, 
chemistry and liver 
tests  X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2  X3 
10mL2 X3 
10mL2 
Blood for Serum   X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  
Plasma  
(includes PCR)   X 
8mL  X 
8mL  X 
8mL  X 
8mL  X 
8mL    
Total volume  10mL  42ml 42mL 42ml 42ml 42ml 34mL  34mL  
Total all study days        268~288 
mL 
1. See SOA in Section 1.2 for specific tests to be performed.  
2. Total volume calculated assumes there are no routine clinical laboratory were done within 48 hours of screening 
that can be used for determining eligibility and no routine clinical laboratory tests were done within the window for 
that visitor 24 hours  of Day 1, 3, 5, 8 and 11 and 48 hours for Day 15 and 72 hours for Day 29 if still hospitalized.  
3. Safety laboratory tests will be collected on Day 15 and 29 if the subject is still hospitalized at these time points or 
if they return for an in -person outpatient visit  and the site has the capacity to collect blood in the outpatient setting. 
8.2.1 Procedures to be Followed in the Event of Abnormal Laboratory Test Values or 
Abnormal Clinical Findings  
If a physiologic parameter (e.g., vital signs, or laboratory value) is outside of the protocol-
specified range, then the measurement may be repeated once if, in the judgment of the investigator, the abnormality is the result of an acute, short-term, rapidly reversible condition or was an error. A physiologic parameter may also be repeated if there is a technical problem with the measurement caused by malfunctioning or an inappropriate measuring d evice (i.e., 
inappropriate- sized BP cuff).  
 
8.2.2 Unscheduled Visits  
If clinical considerations require the subject to be contacted or seen prior to the next schedule 
assessment to assure the subject’s well -being, it is permissible in this protocol.  However, no 
research data is collected at this visit.   
8.3 Adverse Events and Serious Adverse Events  
8.3.1 Definition of Adverse Event (AE)  
AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention- related. An AE can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.  
 Any medical condition that is present at the time that the subject is screened will be considered 
as baseline and not reported as an AE. However, if the severity of any pre- existing medical 
condition increases to severity level 3 or 4, it should be recorded as an AE.  Given the nature of severity of the underlying illness, subjects will have many symptoms and abnormalities in vital signs and laboratory values . All Grade 3  and 4 AEs will be captured as 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 39 of 65 AEs in this trial. In addition, any Grade 2 or higher, suspected drug- related hypersensitivity 
reaction wi ll be reported as an AE  in this trial (see Section 7.1.1). 
 
8.3.2 Definition of Serious Adverse Event (SAE)  
An AE or suspected adverse reaction is considered serious (i.e ., is an SAE) if, in the view of 
either the investigator or the Sponsor, it results in any of the following outcomes: 
• Death ; 
• A life -threatening AE; 
• Inpatient hospitalization or prolongation of existing hospitalization; 
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions; or 
• A congenital anomaly/birth defect. 
 
Important medical events that may not meet the above criteria may be considered serious when, 
based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias, convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.  “Life- threatening” refers to an AE that at occurrence represents an immediate risk of death to a 
subject. An event that may cause death if it occurs in a more severe form is not considered life-threatening. Similarly, a hospital admission for an elective procedure is not considered a SAE.  All SA Es, as with any AE, will be assessed for severity and relationship to study intervention. 
 All SAEs will be recorded on the SAE CRF . 
 All SAEs will be followed through resolution or stabilization by a licensed study physician (for IND studies, a physician listed on the Form FDA 1572 as the site PI or Sub-Investigator).  All SAEs will be reviewed and evaluated by DMID and will be sent to the DSMB  (for periodic 
review), and the IRB/IEC. 
8.3.3 Suspected Unexpected Serious Adverse Reactions (SUSAR)  
A SUSAR is any SAE  where a causal relationship with the study product is at least reasonably 
possible but is not listed in the IIB, Package Insert, and/or Summary of Product Characteristics. 8.3.4 Classification of an Adverse Event 
The determination of seriousness, severity, and causality will be made by an on- site investigator 
who is qualified (licensed) to diagnose AE information, provide a medical evaluation of AEs, 
and classify AEs based upon medical judgment. This includes but is not limited to physicians, 
physician assistants, and nurse practitioners. 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 40 of 65 8.3.4.1 Severity of Adverse Events  
All AEs  and SAEs will be assessed for severity using the DAIDS Table for Grading the Severity 
of Adult and Pediatric Adverse Events, version 2.1 (July 2017).  
 
For AEs not included in the Table, the following guidelines will be used to describe severity. In 
addition, all deaths related to an AE are to be classified as grade 5 according to the DAIDS Table.   
  
• Moderate (Grade 2) : Events that are usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living  and 
causes  discomfort , but poses no significant or permanent risk of harm to the research 
subject.  
 
• Severe (Grade 3) : Events that interrupt usual activities of daily livin g, or significantly 
affect clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. 
 
• Severe (Grade 4) : Events that are potentially life threatening.  
 
• Deaths (Grade 5):  All deaths related to an AE are to be classified as grade 5.  (per DAIDS 
Table).  
 
AEs characterized as intermittent require documentation of onset and duration of each episode. The start and stop dates (d uration) of each reported AE will be recorded on the appropriate CRF . 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of intensity.  
8.3.4.2 Relationship to Study Intervention 
For each reported adverse reaction, the PI or designee must assess the relationship of the event to the study product using the following guideline: 
 
• Related  – There is a temporal relationship between the study intervention and event, and 
the AE is known to occur with the study intervention or there is a reasonable possibility 
that the study intervention caused the AE. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE. 
 
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established. 
8.3.5 Time Period and Frequency for Event Assessment and Follow -Up 
For this study, all G rade 3  and 4 AEs , all SAEs occurring fro m the time the informed consent is 
signed through the Day 29 visit will be documented, recorded, and reported. In addition, any Grade 2 or higher suspected drug- related hypersensitivity reaction s associated with study product 
infusions will be reported as an AE.   
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 41 of 65 8.3.5.1 Investigators Reporting of AEs 
Information on all AEs will be recorded on the appropriate CRF . All clearly related signs, 
symptoms, and results of diagnostic procedures performed because of an AE should be grouped 
together and recorded as a single diagnosis. If the AE is a laboratory abnormality that is part of 
a clinical condition or syndrome, it should be recorded as the syndrome or diagnosis rather than 
the individual laboratory abnormality. Each AE will also be described in terms of duration (start 
and stop date), severity, association with the study product, action(s) taken, and outcome. 
8.3.6 Serious Adverse Event Reporting  
8.3.6.1 Investigators Reporting of SAEs 
Any AE that meets a protocol-defined criterion as a SAE must be submitted within 24 hours of 
site awareness on an SAE form to the DMID Pharmacovigilance Group, at the following address:  
 
DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650 Bethesda, MD 20817, USA SAE Hot Line: 1 -800-537-9979 (US) or 1-301-897-1709 (outside US) 
SAE FAX Number: 1 -800-275-7619 (US) or 1-301-897-1710 (outside US) 
SAE Email Address: PVG@dmidcroms.com  
 Other supporting documentation of the event may be requested by the DMID Pharmacovigilance Group and should be provided as soon as possible. The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on study subject safety and protocol conduct.  At any time after completion of the study, if the site PI or appropriate sub-investigator becomes aware of an SAE  that occurred during the subject’s participation in the study, the site PI or 
appropriate sub-investigator will report the event to the DMID Pharmacovigilance Group. 
8.3.6.2 Regulatory Reporting of SAEs 
Following notification from the site PI or appropriate sub-investigator, DMID, as the IND 
Sponsor, will report any SUSAR in an IND safety report to the FDA and will notify all participating site PIs as soon as possible. DMID will report to the FDA any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but in no case later than 7 
calendar days after the Sponsor ’s initial receipt of the information. If the event is not fatal or life -
threatening, the IND safety report will be submitted within 15 calendar days after the Sponsor determines that the information qualifies for reporting as specified in 21 CFR Part 312.32. Relevant follow up information to an IND safety report will be submitted as soon as the information is available. Upon request from the FDA, DMID will submit to the FDA any additional data or information that the agency deems necessary, as soon as possible, but in no case later than 15 calendar days after receiving the request.  
 SAEs that are not SUSARs will be reported to the FDA at least annually in a summary format which includes all SAEs. 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 42 of 65  
Sites may have additional local reporting requirements (to the IRB and/or national regulatory authority).  
8.3.7 Reporting of Pregnancy  
Pregnancy is not an AE. However, any pregnancy that occurs during study participation should 
be reported to the Sponsor on the appropriate CRF . Pregnancy should be followed to outcome.  
8.4 Unanticipated Problems  
8.4.1 Definition of Unanticipated Problems  
An Unanticipated Problem (UP) is any event, incident, experience, or outcome that meets the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied; 
 Related to participation in the research (mean ing there is a reasonable possibility that the  
incident, experience, or outcome may have been caused by the procedures involved in the research); and  
 Suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. 
8.4.2 Unanticipated Problem Reporting  
To satisfy the requirement for prompt reporting, all UPs  will be reported using the following 
timeline:  
 UPs that are SAEs will be reported to the IRB and to the Statistical and Data Coordinating Center ( SDCC )/study Sponsor within 24 hours of the investigator becoming 
aware of the event per the above describe SAE reporting process.  
 Any other UP will be reported to the IRB and to the SDCC/study Sponsor within 3 days of the investigator becoming aware of the problem. 
9. STATISTICAL  CONSIDERATIONS 
This study is intended to allow for two types of adaptations: 1) sample size re- estimation and 2) 
addition of new experimental arm(s). A brief summary is provided here. Details will be 
described in the statistical analysis plan  (SAP) .  
 
Sample size re- estimation : The target of 400 recoveries corresponds to a total sample size that 
depends on the proportion of subjects who recover by Day 29. This proportion will be evaluated on pooled (i.e., blinded) data to evaluate the total sample size required . A preliminary estimate 
based on a 70% recovery probability is 572 patients.  
 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 43 of 65 Addition of new experimental therapies: If additional data become available to add an 
experimental therapy, the sample size will be updated accordingly. Analyses of newly added 
arm(s) will be performed comparing concurrently enrolled control subjects. This approach was used in the recent PALM study in patients with Ebola virus disease [Mulangu 2019]. Principles 
of adding arms and addressing questions of “when, what and how” to add them will be developed to guide the study team in their decision-making and  will be outlined in a document 
on interim monitoring.  
9.1 Statistical Hypotheses  
 The primary null hypothesis being tested is that time -to-recovery does not differ between the 
experimental and control arms.   A key secondary endpoint is the distribution of the 8-point ordinal scale at Day 15 . For this, the 
parameter of interest is the “common odds ratio,” which quantifies the shift in the severity distribution resulting from treatment. For an efficacious treatment, an odds ratio greater than 1 quantifies an improvement in disease severity; a value of 2 indicates a bigger improvement than a value of 1.25. The null hypothesis to be tested is that the odds of improvement on the ordinal scale is the same for the placebo and experimental treatment arms (i.e., the common odds ratio is 1). It is worth noting that, for large sample sizes, the test based on the proportional odds model is nearly the same as the Wilcoxon rank sum test.  
9.2 Sample Size Determination  
 
Primary endpoint: The log- rank test will be used to compare treatment arms with respect to time 
to recovery. For the log-rank test, the two key determinants of power are the total number of events (i.e., recoveries) E and the treatment -to-control ratio of the rate of recovery, R. The 
number of events required for power 1−𝛽𝛽 to detect a recovery rate ratio of θ using a two- tailed 
test at alpha=0.05 is approximately 
𝐸𝐸=4�1.96+𝑧𝑧
𝛽𝛽�2
{ln(𝜃𝜃)}2, 
where 𝑧𝑧𝛽𝛽 is the 100 (1−𝛽𝛽)th percentile of the standard normal distribution. 
For 85% power, approximately 320 recoveries are required to detect a 40% increase in the rate of 
recovery ( 𝜃𝜃= 1. 40) from remdesivir.  A recovery rate ratio of 1.40 is similar to, but slightly 
higher than the figure of 1.31 reported in Cao, Wang, Wen et al. (2020) for a lopinavir/ritonavir 
trial that used time to improvement by 2 categories as primary endpoint. A total of 400 recoveries is needed for a recovery ratio of 1.35 with 85% power. Table 4 provides power for 
various recovery rate ratio s. 
 Table 4 Number of recoveries needed for 85% power assuming a type I error rate of 5% 
for various recovery ratios.  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 44 of 65 Recovery  ratio 
(θ) Number of recoveries 
needed for 85% 
power  
1.25 723 
1.30 523 
1.35 400 
1.40 318 
 
Key secondary: A sample size can be computed using an (assumed) ordinal scale distribution for 
the placebo and the odds ratio representing clinical improvement. The odds ratio represents the 
odds of improvement in the ordinal scale for treatment relative to placebo [Whitehead, 1993]. 
The sample size to detect a given odds ratio for 1:1 randomization using a 2- tailed test at level α 
is given by 
12�𝑧𝑧α/2+𝑧𝑧β�2
λ2(1−∑𝑝𝑝𝑖𝑖3𝐾𝐾
𝑖𝑖=1), 
 
where λ is the log odds ratio, 𝑝𝑝 𝑖𝑖 is the overall probability (combined over both arms) of being in 
the ith category of the K ordinal outcomes, and 𝑧𝑧α/2 and  𝑧𝑧𝛽𝛽 are the 1−α/2 and 1−β quantiles 
of the standard normal distribution.  
 Table 5 displays five scenarios considered for outcome probabilities in the placebo arm for 
sample size determination. There is significant uncertainty with these assumptions given the 
limited data available. Table 5 shows a range of sample sizes for odds ratios ranging from 1.25 to 
2.5 for 85% power. For 90% power, increase the sample size by 17%. Table 6 displays the 
probabilities of being in different categories of the ordinal scale under an odds ratio of 1.75. A total sample size of 396 gives approximately 85% power to detect an odds ratio of 1.75 using a 
2-tailed test at level α= 0. 05. The categories of the 8 -point ordinal scale are:  
 
• Death;  
• Hospitalized, on invasive mechanical ventilation or ECMO; 
• Hospitalized, on non-invasive ventilation or high flow oxygen devices; 
• Hospitalized, requiring supplemental oxygen; 
• Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care 
(COVID -19 related or otherwise);  
• Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical 
care; 
• Not hospitalized, limitation on activities and/or requiring home oxygen; 
• Not hospitalized, no limitations on activities.  
 
Note that the data elements contributing to this scale will be captur ed separately, in order to 
facilitate different orderings or groupings, as might arise if external data provide information about the clinical course of disease.  
  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 45 of 65 Table 5. Possible scenarios for the distribution of ordinal outcomes for the control arm at 
Day 15. 
 Anticipated  Different scenarios for control arm  
  Scenario 1  Scenario 2  Scenario 3  Scenario 4  Scenario 5  
  more mild disease                        more severe disease  
Severity Outcome  outcome (%)  outcome (%)  outcome (%)  outcome (%)  outcome (%)  
Death  2 1 1 2 3 
Hospitalized, on mechanical 
ventilation or ECMO  1 1 1 1 3 
Hospitalized, on non -
invasive ventilation or high 
flow oxygen devices  2 1 1 2 4 
Hospitalized, requiring 
supplemental oxygen  7 2 5 5 9 
Hospitalized, not requiring 
supplemental oxygen - 
requiring ongoing medical 
care (COVID -19 related or 
otherwise)  8 5 7 17 23 
Hospitalized, not requiring 
supplemental oxygen - no longer requires ongoing 
medical care  10 9 10 20 25 
Not hospitalized, limitation 
on activities and/or requiring 
home oxygen  30 36 35 25 18 
Not hospitalized, no 
limitations on activities  40 45 40 28 15 
 
 Table 6. Sample size calculations for scenarios in  Table 5 for a two -arm study assuming 
85% power, a two-sided type I error rate of 5%, and various true odds ratios.  
True odds 
ratio  Total sample size 
 Scenario 1  Scenario 2  Scenario 3  Scenario 4  Scen ario 5  
1.25 2420  2554  2459  2293  2252  
1.5  744 786 755 700 684 
1.75 396 419 401 370 360 
2.0 262 277 265 243 236 
2.25 194 206 196 179 173 
2.5 154 163 155 141 136 
   
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 46 of 65 Table 7. Treatment ordinal outcome proportions under an odds ratio of 1.75 for five 
scenarios in  Table 6 at Day 15. 
  Scenario  
1 Scenario 
2 Scenario 
3 Scenario 
4 Scenario 
5 
  Anticipated  more mild disease                more severe disease  
Severity Outcome  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Death  2 1.2 1 0.6 1 0.6 2 1.2 3 1.7 
Hospitalized, on mechanical 
ventilation or ECMO  1 0.6 1 0.6 1 0.6 1 0.6 3 1.8 
Hospitalized, on non -invasive 
ventilation or high flow 
oxygen devices  2 1.2 1 0.6 1 0.6 2 1.2 4 2.5 
Hospitalized, requiring 
supplemental oxygen  7 4.3 2 1.2 5 3.0 5 3.1 9 5.8 
Hospitalized, not requiring 
supplemental oxygen - 
requiring ongoing medical care (COVID -19 related or 
otherwise)  8 5.3 5 3.1 7 4.4 17 11.5 23 17.4 
Hospitalized, not requiring 
supplemental oxygen - no longer requires ongoing 
medical care ; 10 7.2 9 5.9 10 6.8 20 16.2 25 24.4 
Not hospitalized, limitation 
on activities and/or requiring 
home oxygen  30 26.5 36 29.3 35 30.2 25 25.9 18 22.7 
Not hospitalized, no 
limitations on activities  40 53.8 45 58.9 40 53.8 28 40.5 15 23.6 
Note that columns may not sum to exactly 100 due to rounding errors.   
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 47 of 65 9.3 Populations for Analyses  
The primary analysis will be based on an intention- to-treat population, including all subjects  
randomized. Similarly, safety analyses will be based a modified intent- to-treat population 
consisting of all subjects  who received at least one infusion. The primary analysis will be based 
on those subjects enrolled in order to 400 recoveries. Subsequent analysis will be performed on 
all enrolled subjects.    
9.4 Statistical Analyses  
9.4.1 General Approach  
This is a double-blind placebo controlled randomized trial testing a superiority hypothesis with a two-sided type I error rate of 5%. Secondary hypotheses have been ordered according to relative 
importance, with one key secondary hypothesis highlighted. These will be described according to the appropriate summary statistics (e.g., proportions for categorical data, means with 95% confidence intervals for continuous data, median for time- to-event data).  
 A statistical analysis plan  will be developed and filed with the study sponsor prior to unblinding 
of study and database lock.   Unblinding of the study will occur after all subjects enrolled for 400 recoveries  have reached the 
end of study, and these visits are monitored and data is cleaned.      
9.4.2 Analysis of the Primary Efficacy Endpoint 
The primary efficacy analysis  is a stratified log -rank test, where stratification is according to 
baseline disease severity  (i.e. protocol defined mild/moderate vs severe disease). Deaths will be 
considered censored at Day 29. 
 
9.4.3 Analysis of the Secondary Endpoint(s)  
 
1) The ordinal scale will be used to estimate a proportional odds model by disease strata. 
The hypothesis test will perform a stratified test to evaluate whether the common odds 
ratio for treatment is equal to one. The distribution of severity results will be summarized by treatment arm as percentages. Efforts to minimize loss -to-follow-up will be 
considerable. However, small amounts of missing data may occur. In such cases, subjects without final outcome data will be excluded from the analysis. Sensitivity analyses will evaluate the impact of making different assumptions about missing observations. These analyses will be defined in the SAP.   
2) Differences in time -to-event endpoints (e.g., time to a t least  a one category improvement 
in ordinal scale) by treatment will be summarized with Kaplan -Meier curves and 95% 
confidence bounds. The same procedure will be used to compare time to at least a two category improvement. 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 48 of 65 3) Change in ordinal scale at specific time poi nts will be summarized by proportions (e.g., 
proportion who have a 1-, 2-, 3-, or 4-point improvement or 1-, 2-, 3-, 4-point 
worsening). 
4) Duration of event (e.g., duration of mechanical ventilation) will be summarized according to median days with quartiles.  
5) Binary data (e.g., incidence of new oxygen use) will be summarized as a percent with 95% confidence intervals. Comparisons between arms will be presented as differences in proportions with 95% confidence intervals. 
6) Categorical data (e.g., 28- day mortality or ordinal scale by day) may be summarized 
according to proportions by category and/or odds ratios with confidence intervals.  
 Procedures for handling missing data, including informative censoring (e.g., a missing duration of oxygen use endpoint due to a death), will be described in the SAP.  
9.4.4 Safety Analyses 
Safety endpoints include death through Day 29, SAEs and Grade 3 and 4 AEs. These events will 
be analyzed univariately and as a composite endpoint. Time- to-event methods will be used f or 
death and the composite endpoint. Each AE will be counted once for a given subject and graded 
by severity and relationship to COVID-19 or study intervention. AEs will be coded using the current version of the Medical Dictionary for Regulatory Activities  (MedDRA). AEs will be 
presented by system organ class, duration (in days), start- and stop- date. Adverse events leading 
to premature discontinuation from the study intervention and serious treatment- emergent AEs 
will be presented either in a table or a li sting.  
 
9.4.5 Baseline Descriptive Statistics  
Baseline characteristics will be summarized by treatment arm. For continuous measures the 
mean and standard deviation will be summarized. Categorical variables will be described by the proportion in each category (with the corresponding sample size numbers).   
9.4.6 Planned Interim and Early Analyses  
Early analyses:  
A blinded sample size re- estimation will be conducted after approximately 115 patients  to 
evaluate the proportion of subjects who have recovered by Day 29, wh ich will provide important 
information about the number of patients needed to achieve 400 recoveries. Additionally, the 
number of deaths will be evaluated.  Additional early analyses include monitoring enrollment, baseline characteristics, and follow-up rates throughout the course of the study by the study team. Analyses will be conducted blinded to 
treatment assignment.  
 
Interim analyses:  
A DSMB will monitor ongoing results to ensure subject  well -being and safety as well as study 
integrity. The DSMB will be asked to recommend early termination or modification only when 
there is clear and substantial evidence of a treatment difference. More details about the interim 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 49 of 65 analyses are described in section 9.4.6.1 and 9.4.6.2 below as well as a separate guidance 
document for the DSMB.  
 
9.4.6.1 Interim Safety Analyses  
Safety analyses will evaluate Grade 3 and 4 AE and SAEs by treatment arm.  Safety monitoring 
will be ongoi ng (see section 10.1.6) and evaluate safety results weekly.  This approach is less 
conservative than what will be used to test for early efficacy results because prov ing definitive 
harm of the experimental agents is not the focus of this study. Pocock stopping boundaries at the looks described correspond to z- scores of (2. 28, 2.29, 2.30). This contrasts with the z- score 
stopping boundaries for the Lan-DeMets spending f unction that mimics O’Brien -Fleming 
boundaries: (3.71, 2.51, 1.99). The unblinded statistical team will prepare these reports for review by the DSMB.   
9.4.6.2 Interim Efficacy Review  
The Lan -DeMets spending function analog of the O’Brien-Fleming boundaries will be used to 
monitor the primary endpoint as a guide for the DSMB for an overall two-sided type- I error rate 
of 0.05. Interim efficacy analyses will be conducted after the blinded sample size re -estimation 
of the primary efficacy endpoint at approximately 33%, 67%, and 100% of total information.  
 
Conditional power will be presented as an additional guide to the DSMB. Conditional power allows computation of the probability of obtaining a statistically significant result by the end of the trial given the data accumulated thus far, incorporating and assuming a hypothesized treatment effect (e.g., the treatment effect assumed for sample size determination) thereafter. If conditional power is less than 20% under the original trial assumptions, consideration should be given to stopping the trial.   The unblinded statistical team will prepare these closed reports for DSMB review and recommendations. Analyses will be presented with blinded codes for treatment arms to protect against the possibility that the DSMB report may fall into the wrong hands. A DSMB c harter 
will further describe procedures and membership. An additional document on statistical issues related to monitoring will be provided to the DSMB prior to interim analyses.   
9.4.7 Sub-Group Analyses 
Subgroup analyses for the primary outcomes will evaluate the treatment effect across the 
following subgroups: geographic region, duration of symptoms prior to enrollment, age, sex  and 
comorbidities . A forest plot will display confidence intervals across subgroups. Interaction tests 
will be conducted to determine whether the effect of treatment varies by subgroup.  
9.4.8 Exploratory Analyses 
An exploratory analysis will compare treatment efficacy estimates according to the various 
scales outlined in section 8.1.3. Specifically, the probability of falling into category “i” or better 
will be compared between arms for each i.   
  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 50 of 65 10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS 
10.1 Regulatory, Ethical, and Study Over sight Considerations  
This study will be conducted in conformity with the principles set forth in The Belmont Report: 
Ethical Principles and Guidelines for the Protection of Human Subjects of Research (US National Commission for the Protection of Human Subj ects of Biomedical and Behavioral 
Research; April 18, 1979), and the federal policy for the Protection of Human Subjects codified in 45 CFR Part 46, 21 CFR Part 50 (Protection of Human Subjects), and the ICH E6 (R2).  
 Each institution engaged in this research will hold an OHRP-approved FWA. OHRP -registered 
IRBs will review and approve this protocol, associated informed consent documents, recruitment 
material, and handouts or surveys intended for the subjects, prior to the recruitment, screening, and enrollment of subjects. The IRB review shall be in accordance w ith 45 CFR 46 and 21 CFR 
50, 21 CFR 56 (IRBs), and other federal, state, and local regulations and policies, as applicable.  Site IRBs may have additional national and local regulations.  Any amendments to the protocol or consent materials will be approved by the IRB before they are implemented. IRB review and approval will occur at least annually throughout the duration of the study. The investigator will notify the IRB of deviations from the protocol and SAEs, as applicable to the IRB policy.  DMID must receive the documentation that verifies IRB -approval for this protocol, informed 
consent documents, and associated documents prior to the recruitment, screening, and enrollment of subjects, and any IRB-approvals for continuing review or amendments as required by the DMID.  
10.1.1 Informed Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a trial and continuing throughout the individual’s trial participation. Investigators or designated research st aff will obtain a subject’s informed consent in accordance with the requirements of 45 
CFR 46, 21 CFR 50 and 21 CFR 56 for FDA-regulated studies, state and local regulations and policy, and ICH E6 GCP before any study procedures or data collection are performed. 
Typically, s ubjects  or the ir legally authorized representatives  (LAR) receive a concise and 
focused presentation of key information about the clinical trial, verbally and with a written 
consent form. Subjects will be asked to read and review the con sent form. Subjects (or LAR ) 
must sign the ICF prior to starting any study procedures being done specifically for this trial. Once signed, a copy of the ICF will be given to the subject or the LAR for their records.  
 For subjects for whom a LAR gave consent, during the course of the study, if the subject regains the capacity to consent, informed consent must be obtained from the subject and the subject offered the ability to leave the study if desired.   
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 51 of 65 However, due to strict respiratory isolation policies, limited access to COVID -19 patient rooms 
and SARS-CoV- 2 transmissibility via droplet-contaminated paper , verbal consent and alternative 
methods of obtaining consent (e.g., by phone) will be allowed if approved by the IRB. In 
addition, if a signed paper copy of the ICF is allowed b y hospital policy, how it will be obtained 
and stored will need to be determined. Any variation from the standard the consent process due 
to isolation and infection control should be sent to the IRB for approval prior to enrollment. T he 
site should document the process in their reg ulatory files and demonstrate that the process has 
IRB concurrence or approval. 
 Regardless of the method for obtaining consent, the key information about the study will be 
organized and presented in lay terminology and language that facilitates understanding why one might or might not want to participate.  The site should translate the consent into non-English 
languages consistent with the local population. Translations should be sent to the sponsor for any necessary back translati ons. New information will be communicated by the site PI to subjects 
who consent to participate in this trial in accordance with IRB requirements. The informed consent document will be updated, and subjects will be re-consented per IRB requirements, if necessary.  
 
10.1.1.1 Requirements for Permission by Parents/Guardians and Assent by Children (in 
case of a minor) 
Not Applicable  
10.1.1.2 Other Informed Consent Procedures  
Subjects will be asked for consent to collect additional blood, the use of residual specimens, and 
samples for secondary research. Extra blood will be drawn for secondary research during each visit when a study blood samples are obtained.   The stored samp les will be labeled with barcodes to maintain confidentiality. Research with 
identifiable samples and data may occur as needed ; however, subject confidentiality will be 
maintained as described for this protocol and with IRB approval.  Samples designated fo r secondary research use may be used for understanding the SARS -CoV-2 
infection, the immune response to this infection, and the effect of therapeutics on these factors.  
Samples will not be used to create immortal cell lines, neither sold for commercial profit. 
Although the results of any future research may be patentable or have commercial profit, 
subjects will have no legal or financial interest in any commercial development resulting from any future research.  
There are no direct benefits to the subject for extra specimens collected or from the secondary research. No results from secondary research will be entered into the subject’s medical record. 
Incidental findings will not be shared with the subject, including medically actionable incidental findings, unless required by law. 
Subjects may withdraw permission to use samples for secondary use at any time. They will need 
to contact the study site and the samples will be removed from the study repository after this 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 52 of 65 study is completed and documentation will be completed that outlines the reason for withdrawal 
of permission for secondary use of samples.   
10.1.2 Study Termination and Closure  
Section 7, Study Intervention Discontinuation and Subject Discontinuation/Withdrawal, 
describes the temporary halting of the study. 
 This study may be prematurely terminated if there is sufficient reasonable cause, including but not limited to:  
• Determination of unexpected, significant, or unacceptable risk to subjects 
• Results of interim analysis  
• Insufficient compliance with protocol requirements 
• Data that are not sufficiently complete and/or not evaluable 
• Regulato ry authorities decide that study should be terminated 
If the study is prematurely terminated, then the site PI will promptly inform study subjects and the IRB as applicable. The site PI will assure appropriate follow -up for the subjects, as 
necessary.  
 The Sponsor will notify regulatory authorities as applicable.  
10.1.3 Confidentiality and Privacy 
Subject confidentiality is strictly held in trust by the participating investigators, their staff, and the Sponsor(s) and their agents. This confidentiality is extended to cover clinical information 
relating to subjects, test results of biological samples, and all other information generated by participation in the study. No identifiable information concerning subjects in the study will be released to any unauthorized third party. Subject confidentiality will be maintained when study 
results are published or discussed in conferences.  The study monitor, other authorized representatives of the Sponsor, representatives of the IRB, and/or regulatory agencies may inspect all documents and records required to be maintained by the investigator, including but not limited to medical records (office, clinic, or hospital) and pharmacy records for the subjects in this study. The clinical study site will permit access to such records.  
 All source records including electronic data will be stored in secured systems in accordance with institutional policies and federal regulations.  All study data and research specimens that leave the site (including any electronic transmission of data) will be identified only by a coded number that is linked to a subject through a code key maintained at the clinical site. Names or readily identifying information will not be released unless DMID approves and it aligns with the consent form, or according to laws for required reporting. 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 53 of 65 10.1.4 Secondary Use of Stored Specimens and Data  
This section applies to those subjects who consented to storage of samples for secondary 
research.  Secondary Human Subject Research is the re- use of identifiable data or identifiable 
biospecimens that were collected from some other ‘‘primary’’ or ‘‘initial’’ activity, such as the data and samples collected in this protocol. Any use of the sample or data for secondary research purposes, however, will be presented in a separate protocol and require separate IRB approval. 
 
Each sample will be labeled only with a barcode and a unique tracking number to protect subject confidentiality. Secondary research with coded samples and data may occur; however, subjec t 
confidentiality will be maintained as described for this protocol. An IRB review of the secondary research using coded specimens is required.  The subject’s decision can be changed at any time by notifying the study doctors or nurses in writing. If the subject subsequently changes his/her decision, the samples will be destroyed if the samples have not been used for research or released for a specific research project.  
10.1.4.1 Data Sharing for Secondary Research 
Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de -identification. The SAP and Analytic 
Code will also be made available. This data will be available immediately following publication, with no end date.   The investigator may request removal of data on individual study subjects from NIH data 
repositories in the event that a research subject withdraws or changes his or her consent. However, some data that have been distributed for approved research use cannot be retrieved.  
10.1.5 Key Roles and Study Governance 
The study is sponsored by DMID. Decisions related to the study will be made by a protocol team that includes representatives from all countries, and separate networks within a country. 
10.1.6 Safety Oversight 
10.1.6.1 Protocol team oversight 
A subset of the protocol team will review blinded pools of AE data every 2 weeks to ensure no 
significant number of unexpected AEs (AEs that do not fit with the known course of COVID-19). If there are a significant number of unexpected AEs, the DSMB will be asked to review unblinded safety data in an ad hoc meeting.  
10.1.6.2 Data Safety Monitoring Board 
Safety oversight will be conducted by a DSMB that is an independent group of experts that 
monitors subject safety and advises DMID. The DSMB members w ill be separate and 
independent of study personnel participating in this trial and should not have scientific, financial or other conflicts of interest related to this trial. The DSMB will consist of members with appropriate expertise to contribute to the interpretation of the data from this trial.  The DSMB 
should be as broadly informed as possible regarding emerging evidence from related studies. The DSMB will operate under the guidelines of a DMID -approved charter that will be written at the 
organizational meeting of the DSMB. The DSMB will review SAEs on a regular basis and ad 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 54 of 65 hoc during this trial. The DMID Medical Monitor will be responsible for reviewing SAEs in real 
time. The DSMB will review SAEs on a regular basis and ad hoc during this trial. 
 The DSMB will conduct the following reviews: 
• Electronic access to safety data after every 50 subjects are dosed.  If this trigger occurs 
more  frequently  than every 4 weeks, then the meeting can be delayed until approximately 
4 weeks after the last meeting . 
• Formal reviews of safety/efficacy after approximately  200 subjects have met recovered 
status . 
• Ad hoc meeting if the protocol team raises any concerns 
• A final review  meeting after final clinical database lock, to review the cumulative 
unblinded safety data for this trial.  
 The study will not stop enrollment awaiting these DSMB reviews, al though the DSMB may 
recommend temporary or permanent cessation of enrollment bas ed on their safety reviews.  
  Additional data may be requested by the DSMB, and interim statistical reports may be generated as deemed necessary and appropriate by DMID. The DSMB may receive data in aggregate and presented by treatment arm. The DSMB may al so be provided with expected and observed rates 
of the expected AEs in an unblinded fashion and may request the treatment assignment be unblinded for an individual subject if required for safety assessment. The DSMB will review grouped and unblinded data in the closed session only. At  each meeting, the DSMB will make a 
recommendation as to the advisability of proceeding with study interventions (as applicable), and to continue, modify, or terminate this trial.  
 
10.1.7 Clinical Monitoring  
Clinical site monitoring i s conducted to ensure that the rights and well- being of trial subjects are 
protected and  that the reported trial data are accurate, complete, and verifiable. Clinical 
monitoring also ensures that conduct of the trial is in compliance with the currently approved 
protocol/ amendment(s), ICH, GCP, and with applicable regulatory requirement(s) and Sponsor 
requirements. Clinical monitoring will also verify that any critical study procedures are completed following specific instructions in the protocol- specific MOP . 
 Monitoring for this study will be performed by DMID or their designee. Details of clinical site monitoring are documented in a clinical monitoring plan  (CMP ). The CMP describes in detail 
who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports. Monitoring visits will include, but are not limited to, review of regulatory files, accountability records, CRF s, 
ICFs, medical and laboratory reports, site study intervention storage records, training records, and protocol and GCP compliance. Site monitors will have access to each participating site, study personnel, and all study documentation according to the DMID-approved site monitoring plan. Study monitors will meet with site PIs to discuss any problems and outstanding issues and will document site visit findings and discussions. 
10.1.8 Data Handling and Record Keeping  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 55 of 65 10.1.8.1 Data Collection and Management Responsibilities 
Data collection is the responsibility of the study personnel at the participating clinical study site 
under the supervision of the site PI. The site PI must maintain complete and accurate source documentation.  Clinical research data from source documentation (including, but not limited to, AE/SAEs, concomitant medications, medical history, physical assessments, clinical laboratory data) will be entered by the clinical study site into CRF s via a 21 CFR Part 11- compliant internet data entry 
system provided by the SDCC. The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. AEs and concomitant medications will be coded according to the most current versions of MedDRA and W HODrug, respectively. 
 The SDCC for this study will be responsible for data management, quality review, analysis, and reporting of the study data.  The IND Sponsor is responsible for review of data collection tools and processes, and review of 
data and repor ts. 
 A separate study specific Study Data Standardization Plan (SDSP) appendix will be developed which describes the technical recommendations for the submission of human study data and related information in a standardized electronic format throughout product development.  
 At the end of the study, a copy of all datasets including annotated CRFs and data dictionary will be provided to DMID. 
10.1.8.2 Study Record Retention  
Study related records, including the regulatory file, study product accountability records, consent 
forms, subject source documents and electronic records should be maintained for a period of 2 years following the date a marketing application is approved for the investigational product for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and FDA is notified. These documents should be retained for a longer period, however, if required by local policies or regulations. No records will be destroyed without the written consent of DMID. Consent forms with specimen retention linked to identifiable specimens will be maintained for as long as the specimens remain in identifiable format, and a minimum of three years after use of the identifiable specimens in nonexempt human subject 
research.  
10.1.8.3 Source Records  
Source data are all information in original records (and certified copies of original records) of clinical findings, observations, or other acti vities in a clinical trial necessary for the 
reconstruction and evaluation of the trial. Source data should be attributable, legible, contemporaneous, original, accurate, and complete. Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH GCP, regulatory, 
and institutional requirements. Data recorded in the CRF  derived from source documents should 
be consistent with the data recorded on the source documents.  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 56 of 65  
It is understood that biocontainme nt may necessitate alternative processes for storing  consents 
and other source documents. Each site will determine and document this process.  Interview of subjects is sufficient for obtaining medical history. Solicitation of medical records from the subject’s primary care provider is not required. 
10.1.9  Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, any process that is 
noted in the protocol and refers to details in the protocol- specific MOP, or GCP requirements o r 
any critical study procedures with specific instructions in ancillary documents referenced in the protocol such as a protocol- specific MOP.  
 The noncompliance may be either on the part of the subject, the investigator, or the study site staff. Following a deviation(s), corrective actions should be developed by the site and implemented promptly. All individual protocol deviations will be addressed in subject study records.  
 It is the responsibility of the site PI and personnel to use continuous vigilance to identify and report deviations within five working days of identification of the protocol deviation, or within five working days of the scheduled protocol-required activity. All deviations must be promptly reported to DMID per the protocol deviation reporting procedures. Protocol deviations must be sent to the local IRB/IEC per their guidelines. The site PI and personnel are responsible for knowing and adhering to their IRB requirements. A completed copy of the DMID Protocol Deviation Form must be maintained in the Regulatory File, as well as in the subject’s chart if the deviation is subject specific.  
10.1.10 Publication and Data Sharing Policy 
Following completion of the study, results of this research will be published in a scientific 
journal. As this is an adaptive study and given the public health urgency to disseminate results, data from individual comparisons (i.e. the initial 2 study arms) can be published when those arms are fully enrolled and all subjects in those arms are followed through to completion of the study.   Data will be available immediately following publication, with no end date, with data sharing at the discretion of the Sponsor. Sites may also obtain individual or country level data from the database for separate publications is  desired.  Publication may occur prior to completion of a final 
clinical study report for the entire trial.  
10.1.11 Human Data Sharing Plan 
This study will be conducted in accordance with the following publication and data sharing 
policies and regulations: 
• NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication.  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 57 of 65 10.1.12 Publication  
Following completion of the study, the protocol team is expected to publish the results of this 
research in a scientific journal. This study will adhere to the following publication and data sharing policies and regulations:  
• This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. As such, the final peer-reviewed journal manuscripts will accessible to the public o n PubMed Central no later 
than 12 months after publication. 
10.1.13 Conflict of Interest Policy  
The independence of this study from any actual or perceived influence, such as by the pharmaceutical industry, is critical. Therefore, any actual conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be required to have such conflicts managed in a way that is appropriate to their participation in the design and conduct of this trial. DMID has established policies and procedures for all study group members to disclose all conflicts of interest and will establish a mechanism for the management of all reported  dualities of interest.  
10.2 Additional Considerations  
10.2.1 Research Related Injuries  
For any potential research related injury, the site PI or designee will assess the subject. Study personnel will try to reduce, control, and treat any complications from this study. Immediate medical treatment may be provided by the participating study site. As needed, referrals to appropriate specialist or other health care facilities will be provided to the subject. The site PI should then determine if an injury occurred as a dire ct result of the tests or treatments that are 
done for this trial.  Immediate medical treatment may be provided by the participating site, such as giving emergency medications to stop immediate allergic reactions.  No financial compensation will be 
provided to the subject by NIAID, NIH or the participating site for any injury suffered due to participation in this trial.  
 
10.3 Abbreviations  
Abbreviation  Definition  
AE Adverse Event  
ALT  Alanine Transaminase  
AST  Aspartate Transaminase  
BP Blood Pressure  
CFR  Code of Federal Regulations  
CI Confidence Interval  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 58 of 65 Abbreviation  Definition  
CMS  Clinical Material Services  
Cr Creatinine  
CRF  Case Report Form  
CROMS  Clinical Research Operations and Management Support  
CSR  Clinical Study Report  
CQMP  Clinical Quality Management Plan  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases  
EC Ethics Committee  
EMR  Electronic Medical Record  
FDA  Food and Drug Administration  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
Hgb Hemoglobin  
HR Heart Rate  
IB Investigator’s Brochure  
ICD International Classification of Diseases  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IND Investigational New Drug Application  
IRB Institutional Review Board  
IV Intravenous  
MCG  Microgram  
MedDRA  Medical Dictionary for Regulatory Activities  
MERS  Middle East Respiratory Syndrome  
MOP  Manual of Procedures  
N Number (typically refers to subjects)  
NDA  New Drug Application  
NEWS  National Early Warning Score  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
OP Oropharyngeal  
PHI Protected Health Information  
PI Principal Investigator  
PLT Platelet  
PP Per Protocol  
PT Prothrombin Time  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS  Severe Acute Respiratory Syndrome  
SDCC  Statistical and Data Coordinating Center  
SDSP  Study Data Standardization Plan  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 59 of 65 Abbreviation  Definition  
SNP Single Nucleotide Polymorphisms  
SOA  Schedule of A ssessments  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T. Bili  Total Bilirubin  
UP Unanticipated Problem  
US United States  
WBC  White Blood Cell  
10.4 Protocol Amendment History 
Version/Date    
Section  Description of 
Change  Brief Rationale 
2.0 
2MAR2020    
 Overall  This version addresses the comments received from 
the US FDA, Japanese PDMA, DSMB, IRBs, and 
NIAID scientific review.  
 Improved clarity and 
brevity Multiple areas throughout the document were 
reworded to improve clarity (recognized after 
implementation) and edited to minimize redundant 
statements.  
1.1 Number of sites 
increased from 50 to 
approximately 75  Given the currently unpredictable epidemiology, 
additional sites will improve the ability to enroll the 
study in a timely manner.  
 Sample size increased  Version 1 sa mple size table and statements in the text 
did not align. The new assumptions use a slightly 
smaller treatment effect (OR 1.75) and the 8 -
category scale and give the sample size of 440.  
 Addition of phone call 
on Day 22 Recent information from the outbrea k in China 
suggest some COVID-19 patients worsen between 2 
and 4 weeks of illness. We added Day 22 because of 
concerns that the peak illness may be missed.  There 
are also concerns if the more severe population will 
be discharged by Day 29.  
 Ordinal scale was 
increased to 8 
categories.  This addresses the concern raised by several reviews 
that “Hospitalized not on oxygen” is two separate 
populations – those still needing medical care and 
those kept in hospital just for infection control.  
 Objectives and 
endpoints were put 
into table format  Multiple comments that the tabular form of 
objectives and endpoints (that was previously in 
Section 4) was much easier to read and understand.  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 60 of 65  Added inclusion 
criteria for admission 
to hospital  This was implied throughout the document, but never 
stated in the inclusion criteria.  
 Inclusion criteria #8  Contraceptive requirement aligned to new IB from 
February 21, 2020  
 Phase of study Changed to phase 3. After discussion with company, 
and new IB that outlines safety data of > 500 
subjects, the company thought this was more 
accurately called a  phase 3 trial.  
1.2 Schedule of 
Assessments updated  To include Day 22. Footnotes also revised for clarity. 
2.2 Background updated To reflect current understanding of SARS -CoV, 
COVID -19, and new data from IB.  
3. Separating objectives 
about non-invasive 
from invasive 
mechanical 
ventilation  Elsewhere in the protocol, it was mentioned that this 
data would be captured separately, but it mistakenly 
never made into an endpoint. 
 Added Day 14 
mortality  To allow better assessment of short and long term 
mortality.  
4 Rewritten for clarity  These paragraphs were substantially rewritten, but 
aside from the changes note above the content is not 
different.  
8 Screening is more 
detailed  These edits reflect so ambiguity discovered with the 
first enrollment.  
8.1.2 Efficacy assessments 
more detailed  More detail is provided to facilitate these 
assessments. Also, each component that contribute to 
the categories will not be captured separately. This 
will allow the ordinal scale as structured, but also 
will allow  analysis of alternative ordinal scales.  
8.1.3.1 Viral load in plasma 
and resistance  The assessment of viral load in plasma and detection 
of resistance was previously noted on the SOA, but 
never discussed in the text. This has now been added 
in this section.  
9.2 Sample size 
calculations  With the addition of one category to the ordinal 
scale, the estimates per category must change leading 
to new tables.  
3.0 
27MAR2020    
 Improved clarity  Multiple areas throughout the document were 
reworded to improve clarity (issues that arose with  
implementation)  
 Flexibility  The pandemic has limited ability for people to be 
seen in followup due to infection control and 
restrictions on travel.  Additionally, staff at some sites 
have limited ability to go into rooms  due to limited 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 61 of 65 personal protective equipment.  So flexibility has 
been added where possible while still ensuring safety 
and good scientific data.  
1.1 Sample Size Increase  The sample size was changed to reflect ensuring 
sufficient samples for the endpoint of interest which 
400 subjects with a “recovered” status (per the 
primary objective). Additionally, enrollment is 
permitted after the 400 recoveries up to April 20 to 
provide additional da ta about important subgroup s. 
 Primary Endpoint Given evolving data, the precise day of assessment 
of the primary endpoint is not clear. Modeling of the 
prior endpoint suggested if the day is chosen 
incorrectly, the power is significantly decreased. So 
the primary endpoint has been changed from a 
ordinal scale on a given day to days to recovery (the 
best three categories of the ordinal scale.   
 Key secondary 
endpoint  The prior primary endpoint has been labeled as the 
key secondary endpoint.  
 Inclusion Cr iteria #5  Given delays of PCR results in some sites (given 
number of tests and throughput within the lab), the 
PCR positive requirement has been written to allow 
flexibility if the PCR results are delayed.  
 Inclusion Criteria #6  Removed auscultation requ irement given challenges 
of accurate auscultation while in full PPE.   
 Exclusion Criteria #2 Cutoff of eGFR to 30 was decreased after discussion 
with the manufacturer and FDA.   
 Sites  Increased to 100 given unpredictable epidemiology 
of COVID -19 
 DSMB  Given the rapid pace of enrollment, the prior plans 
for DSMB oversight are not practical, so this has 
been modified with input from the DSMB on when 
they would like to have interim reviews.  
2.3.2 Drug interaction Corrected erroneous statements about  CYP 
inhibition.  
5.3 Vulnerable Subjects  Allow inclusion of those that are incapable of 
consent such as cognitively impaired. Prior version 
noted consent by a LAR, but it was not described in 
this section.  
6 Study Product Updated throughout for 2 issues.  First, the newly 
manufactured lot of remdesivir is in 100mg vials. 
Second, there is limited supply of placebo and the 
options for using saline with an opaque bag for the 
control infusion was added.  
6.5 Concomitant Therapy There has been significa nt increased in use of off 
label therapies for COVID -19, including many 
repurposed agents and therapies targeting immune 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 62 of 65 11. REFERENCES 
 
1. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, 
Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person- to-person transmission: a study of a family cluster. The 
Lancet. Jan 24. pii: S0140-6736(20)30154-9. doi: 10.1016/S0140-6736(20)30154-9. 
2. Wu JT, Leung K, Leung GM. 2020. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet, Jan 31. pii: S0140-6736(20)30260-9. doi: 10.1016/S0140-6736(20)30260-9. 
3. M. K. Lo et al., GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 7, 43395 (2017).  
4. T. K. Warren et al., Therapeutic efficacy of the small molecule GS -5734 against Ebola 
virus in rhesus monkeys. Nature 531, 381–385 (2016). 
5. M. K. Lo et al., Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci. Transl. Med . 11, eaau9242 (2019). 
6. Mulangu S. et. al. J. N Engl J Med. 2019 Nov 27. doi: 10.1056/NEJMoa1910993. PMID: 31774950. 
7. T. P. Sheahan et al., Broad- spectrum antiviral GS -5734 inhibits both epidemic and 
zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017).  
8. T. P. Sheahan et al., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222 (2020). response.  So additional wording was added to cover 
these scenarios to minimize additional confounding 
medications.  
8.1.3 Sample Processing  Some sites are reporting needing to process samples 
in BSL-3 and/or have limitations on processing, 
shipping, storage, etc. of samples. So wording was 
added to allow exclusion of these samples (which 
may be cost prohibitive)   
8.2 Venipuncture volume This table was corrected for total volumes, but not 
new samples were added.  
9 Statistical 
Considerations  This section was rewritten to given the change in 
sample size.  
10.1.1 Informed consent Given isolation and infection control issues with 
COVID-19, traditional consenting documentation is 
not always possible. This section was rewritten to 
allow alternative consent processes and 
documentation as long as these are acceptable to the 
site’s IRB.  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 63 of 65 9. M. L. Agostini et al., Coronavirus susceptibility to the antiviral remdesivir (GS -5734) is 
mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9, 
e00221-18 (2018). 
10. E. de Wit et al., Middle East respiratory syndrome coronavirus (MERS- CoV) causes 
transient lower respiratory tract infection in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 110, 16598–16603 (2013). 
11. E. de Wit et al., Prophylactic and therapeutic remdesivir (GS-5734) treatment in the 
rhesus macaque model of MERS -CoV infection. Proc. Natl. Acad. Sci. U.S.A. (2020). 
12. [STUDY_ID_REMOVED]: A Phase 3 Randomized, Double-blind, Placebo- controlled, Multicenter 
Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease (Opened Feb 6, 2020). 
13. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003;9:399–406. 
14. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syn drome: a preliminary study. JAMA 2003;290:3222–3228. 
15. Wong VW, Dai D, Wu AK, et al. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003;9:199–201. 
16. Barnard DL, Hubbard VD, Burton J, et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D- N4-
hydroxycytidine. Antivir Chem Chemother 2004;15:15–22. 
17. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and  clinical findings. Thorax 2004;59:252–256. 
18. Cinatl J Jr, Michaelis M, Scholz M, et al. Role of interferons in the treatment of severe acute respiratory syndrome. Expert Opin Biol Ther 2004;4:827–836. 
19. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated inte rferon -alpha protects type 1 
pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004;10:290–293. 
20. Hensley LE, Fritz LE, Jahrling PB, et al. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis 2004;10:317–319. 
21. Stroher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 2004;189:1164–1167. 
22. Tan EL, Ooi EE, Lin CY, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004;10:581–586. 
23. Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004;318:719–725. 
24. Zheng B, He ML, Wong KL, et al. Potent inhibition of SARS- associated coronavirus 
(SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN -gamma). J Interferon Cytokine Res 2004;24:388–390. 
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 64 of 65 25. Cinatl J, Morgenstern B, Bauer G, et al. Glycyrrhizin, an active component of liquorice 
roots, and replication of SARS-associated coronavirus. Lancet 2003;361:2045–2046. 
26. Groneberg DA, Poutanen SM, Low DE, et al. Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis 2005;5:147–155. 
27. Mair‐ Jenkins J, Saavedra‐Campos M,  Baillie JK, et al.  The effectiveness of convalescent 
plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta‐analysis. J Infect  
Dis. 2015; 211( 1):  80‐ 90. 
28. Public Health England. Treatment of MERS- CoV: information for clinicians. Clinical 
decision -making support for treatment of MERS-CoV patients. September 2015. 
https://www.gov.uk/government/uploads/system/uploads/attachment_data / 
file/459835/merscov_for_clinicians_sept2015.pdf.  
29. Chan, J.F., et al., Broad- spectrum antivirals for the emerging Middle East respiratory 
syndrome coronavirus. J Infect, 2013. 67(6): p. 606-16.  
30. Cheng, K.W., et al., Thiopurine analogs and mycophenolic aci d synergistically inhibit the 
papain -like protease of Middle East respiratory syndrome coronavirus. Antiviral Res, 
2015. 115: p. 9-16.  
31. Wang, Y., et al., Coronavirus nsp10/nsp16 Methyltransferase Can Be Targeted by nsp10-Derived Peptide In Vitro and In Vivo To Reduce Replication and Pathogenesis. J Virol, 2015. 89(16): p. 8416-27. 
  
Protocol 20-0006 Version 3.0 
Adaptive COVID- 19 Treatment Trial (ACTT)   2 April  2020 
DMID/NIAID/NIH  CONFIDENTIAL  Page 65 of 65 Country specific appendix  
The following language applies only to Clinical Research Sites located in the United States.  
10.2.2 Public Readiness and Emergency Preparedness Act  
The drug Remdesivir and the efforts for this clinical trial are covered under the Public Readiness 
and Emergency Preparedness Act (PREP Act) and the Declaration issued by the Secretary of the U.S. Department of Health and Human Services under that Act. Under the PREP Act and the Declaration, covered persons (such as manufacturers, distributers, program planners, and other qualified persons who prescribe, administer or dispense study product) are immune from liability from the administration , or use of a covered countermeasure, such as Remdesivir . The PREP 
Act provides immunity for covered persons from liability, unless the injury was caused by willful misconduct. The Declaration invoking the PREP Act for COVID-19 covered countermeasures was  made on March 17, 2020 and is retroactively effective from February 4, 
2020. 
The PREP Act also established the Countermeasures Injury Compensation Program (CICP) to 
provide compensation for serious injuries or death that occur as the direct result of the administration or use of certain countermeasures. Any requests for compensation must be filed within one year of the administration or use of the covered countermeasure. Requests for Benefits must be made to the Health Resources and Services Administration ’s (HRSA) 
Countermeasures Injury Compensation Program (http://www.hrsa.gov/cicp/) by filing a Request for Benefits Form and all required medical records and supporting documentation. Additional information on filing a Request for Benefits is available on t he CICP’s website at 
http://www.hrsa.gov/cicp/.  Compensation may then be available for reasonable and necessary medical benefits, lost wages and/or death benefits to eligible individuals for certain injuries in accordance with regulations published by the Secretary of HHS (found at 42 CFR part 110).  
If an individual suffers a serious physical injury or death from the administration or use of a 
covered countermeasure in this study, the individual, the individual’s legal or personal representative, the admi nistrator/executor of a deceased individual’s estate, or certain survivors 
may request benefits from the CICP.  A serious physical injury means an injury that warranted hospitalization (whether or not the person was actually hospitalized) or that led to a significant loss of function or disability. The CICP is the payer of last resort. This means that it only covers expenses or provides benefits that other third-party payers (such as health insurance, the Department of Veterans Affairs, or Workers’ Compensation programs) do not have an obligation to pay. 
If the Secretary of HHS does not make a final determination on the individual’s request within 
240 days, or if the individual decides not to accept the compensation, the injured individual or his representat ive may pursue a tort claim in the US District Court for the District of Columbia, 
but only if the claim involves willful misconduct and meets the other requirements for suit under the PREP Act. Any award is reduced by any public or private insurance or worker’s compensation available to the injured individual. Awards for non- economic damages, such as 
pain, suffering, physical impairment, mental anguish, and loss of consortium are also limited. If the individual accepts compensation, or if there is no willful misconduct, then the individual does not have a tort claim that can be filed in a US Federal or a State court.  